



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification:</b> A61K 38/17, A61K 38/18, C07K 14/435, C07K 14/475, C12N 1/21, C12N 5/10, C12N 15/12, C12N 15/64, C12N 15/66, G01N 33/53	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/12117</b> <b>(43) International Publication Date:</b> 09 March 2000 (09.03.2000)
<b>(21) International Application Number:</b> PCT/US99/19046	<b>Published</b>	
<b>(22) International Filing Date:</b> 20 August 1999 (20.08.1999)		
<b>(30) Priority Data:</b> 60/098,440 31 August 1998 (31.08.1998) US 60/098,453 31 August 1998 (31.08.1998) US 60/106,462 30 October 1998 (30.10.1998) US 60/111,588 09 December 1998 (09.12.1998) US		
<b>(60) Parent Application or Grant</b> ELI LILLY AND COMPANY [/]; (). EDMONDS, Brian, Taylor [/]; (). SU, Wen [/]; (). EDMONDS, Brian, Taylor [/]; (). SU, Wen [/]; (). CONRAD, Robert, A. ; ().		
<b>(54) Title: Wnt HOMOLOG NUCLEIC ACIDS, POLYPEPTIDES, METHODS, USES</b> <b>(54) Titre: ACIDES NUCLEIQUES, POLYPEPTIDES HOMOLOGUES DE Wnt, PROCEDES ET UTILISATIONS</b>		
<b>(57) Abstract</b> <p>The present invention relates to at least one novel Wnt homolog polypeptide, including isolated nucleic acids that encode at least one Wnt-4AF and Wnt-5C homolog polypeptide, Wnt-4AF and Wnt-5C homolog polypeptides, vectors, host cells, transgenics, chimerics, and methods of making and using thereof, as well as Wnt-4AF and Wnt-5C homolog-specific antibodies and methods.</p> <b>(57) Abrégé</b> <p>L'invention concerne au moins un nouveau polypeptide homologue de Wnt, y compris des acides nucléiques isolés qui codent au moins un polypeptide homologue de Wnt-4AF et Wnt-5C, des polypeptides homologues de Wnt-4AF et Wnt-5C, des vecteurs, des cellules hôtes, des transgènes, des chimères et des procédés pour les produire et les utiliser, ainsi que des anticorps spécifiques des homologues de Wnt-4AF et Wnt-5C et des procédés.</p>		

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> A61K 38/17, 38/18, C07K 14/435, 14/475, C12N 1/21, 5/10, 15/12, 15/64, 15/66, G01N 33/53	<b>A1</b>	<b>(11) International Publication Number:</b> WO 00/12117  <b>(43) International Publication Date:</b> 9 March 2000 (09.03.00)											
<b>(21) International Application Number:</b> PCT/US99/19046  <b>(22) International Filing Date:</b> 20 August 1999 (20.08.99)  <b>(30) Priority Data:</b> <table border="0" style="width: 100%;"><tr><td style="width: 33%;">60/098,453</td><td style="width: 33%;">31 August 1998 (31.08.98)</td><td style="width: 33%;">US</td></tr><tr><td>60/098,440</td><td>31 August 1998 (31.08.98)</td><td>US</td></tr><tr><td>60/106,462</td><td>30 October 1998 (30.10.98)</td><td>US</td></tr><tr><td>60/111,588</td><td>9 December 1998 (09.12.98)</td><td>US</td></tr></table> <b>(71) Applicant (for all designated States except US):</b> ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> EDMONDS, Brian, Taylor [US/US]; 12990 Brighton Lane, Carmel, IN 46032 (US). SU, Wen [CN/US]; 13447 Dunes Drive, Carmel, IN 46032 (US).  <b>(74) Agents:</b> CONRAD, Robert, A. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).	60/098,453	31 August 1998 (31.08.98)	US	60/098,440	31 August 1998 (31.08.98)	US	60/106,462	30 October 1998 (30.10.98)	US	60/111,588	9 December 1998 (09.12.98)	US	<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
60/098,453	31 August 1998 (31.08.98)	US											
60/098,440	31 August 1998 (31.08.98)	US											
60/106,462	30 October 1998 (30.10.98)	US											
60/111,588	9 December 1998 (09.12.98)	US											
<b>(54) Title:</b> Wnt HOMOLOG NUCLEIC ACIDS, POLYPEPTIDES, METHODS, USES													
<b>(57) Abstract</b>  The present invention relates to at least one novel Wnt homolog polypeptide, including isolated nucleic acids that encode at least one Wnt-4AF and Wnt-5C homolog polypeptide, Wnt-4AF and Wnt-5C homolog polypeptides, vectors, host cells, transgenics, chimerics, and methods of making and using thereof, as well as Wnt-4AF and Wnt-5C homolog-specific antibodies and methods.													

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Description**

5

10

15

20

25

30

35

40

45

50

55

-1-

**Wnt HOMOLOG NUCLEIC ACIDS, POLYPEPTIDES, METHODS, USES****BACKGROUND OF THE INVENTION****CROSS-REFERENCE**

This application claims the benefit of U.S. Provisional Application Nos. 60/098453 filed August 31, 1998; 60/098440 filed August 31, 1998; 60/106462 filed October 30, 1998; and 60/111588 filed December 9, 1998, each of which applications are entirely incorporated herein by reference.

**FIELD OF THE INVENTION**

The present invention relates to compounds and compositions comprising novel Human Wnt Homolog (Wnt homolog) polypeptides, nucleic acids, host cells, transgenics, chimerics, antibodies, compositions, and methods of making and using thereof.

**RELATED ART**

Extensive studies have illustrated the fundamental roles of Wnt genes in numerous biological decisions during embryonic development. These include not only the control of cellular proliferation but also the establishment of cell fates. Wnt genes encode a large family of secreted molecules and have been identified in *Drosophila*, *Caenorhabditis elegans*, *Xenopus*, zebrafish, mouse and humans. They act as developmental regulators that can elicit different biological responses depending upon the cellular context.

-2-

Soluble Wnt proteins bind to the Frizzled class of membrane proteins on target cells and thereby upregulate gene expression via the -catenin cytoplasmic intermediate. It is now apparent that Wnts identify a major class of signaling molecules comparable in importance to other secreted peptides such as FGFs, Hedgehogs and TGF-beta. While clearly important in developmental processes, the role of Wnt genes / proteins in adults is unclear.

Accordingly, there is a need to provide Wnt-4AF and Wnt-5C homolog polypeptides, nucleic acids, host cells, transgenics, chimerics, as well as methods of making and using thereof.

#### SUMMARY OF THE INVENTION

The present invention provides isolated nucleic acids and encoded Wnt homolog polypeptides, including specified fragments and variants thereof, as well as Wnt homolog compositions, probes, primers, vectors, host cells, antibodies, transgenics, chimerics and methods of making and using thereof, as described and enabled herein.

The present invention provides, in one aspect, isolated nucleic acid molecules comprising or complementary to a polynucleotide encoding specific Wnt-4AF and Wnt-5C homolog polypeptides, as fragments or specified variants, comprising at least one domain thereof.

Such polypeptides are provided as non-limiting examples by the corresponding domains, specified fragments and/or specified variants of Wnt-4AF and Wnt-5C homolog polypeptides corresponding to at least 90-100% of the

5

-3-

10

contiguous amino acids of at least one of SEQ ID NOS:2, 4, 6 & 8, respectively.

15

The present invention further provides recombinant vectors, comprising 1-40 of said isolated Wnt-4AF and Wnt-5C homolog nucleic acid molecules of the present invention, host cells containing such nucleic acids and/or recombinant vectors, as well as methods of making and/or using such nucleic acid, vectors and/or host cells.

20

The present invention also provides methods of making or using such nucleic acids, vectors and/or host cells, such as but not limited to, using them for the production of Wnt-4AF and Wnt-5C homolog nucleic acids and/or polypeptides by known recombinant, synthetic and/or purification techniques, based on the teaching and guidance presented herein in combination with what is known in the art.

30

The present invention also provides an isolated Wnt-4AF and Wnt-5C homolog polypeptide, comprising at least one fragment, domain or specified variant of at least 90-100% of the contiguous amino acids of at least one portion of at least one of SEQ ID NOS:2, 4, 6 & 8.

35

The present invention also provides an isolated Wnt-4AF and Wnt-5C homolog polypeptide as described herein, wherein the polypeptide further comprises at least one specified substitution, insertion or deletion corresponding to portions or residues of at least one of SEQ ID NOS:2, 4, 6 & 8.

40

45

The present invention also provides an isolated Wnt-4AF and Wnt-5C homolog polypeptide as described herein, wherein the polypeptide has at least one activity, such as, but not

50

55

5

-4-

10

limited to, Apoptosis or transforming activities .  
caharacterized using well-known assays. A Wnt-4AF and Wnt-  
5C homolog polypeptide can thus be screened for a  
corresponding activity according to known methods.

15

5 The present invention also provides a composition  
comprising an isolated Wnt-4AF and Wnt-5C homolog nucleic  
acid and/or polypeptide as described herein and a carrier or  
diluent. The carrier or diluent can optionally be  
pharmaceutically acceptable, according to known methods.

20

10 The present invention also provides an isolated nucleic  
acid probe, primer or fragment, as described herein, wherein  
the nucleic acid comprises a polynucleotide of at least 10  
nucleotides, corresponding or complementary to at least 10  
nucleotides of at least one of SEQ ID NOS:1, 3, 5, & 7 , or  
15 a consensus sequence thereof.

30

The present invention also provides a recombinant  
vector comprising an isolated Wnt-4AF and Wnt-5C homolog  
nucleic acid as described herein.

35

The present invention also provides a host cell,  
20 comprising an isolated Wnt-4AF and Wnt-5C homolog nucleic  
acid as described herein.

40

The present invention also provides a method for  
constructing a recombinant host cell that expresses a Wnt-  
4AF and Wnt-5C homolog polypeptide, comprising introducing  
25 into the host cell a Wnt-4AF and Wnt-5C homolog nucleic acid  
in replicatable form as described herein to provide the  
recombinant host cell. The present invention also provides  
a recombinant host cell provided by a method as described  
45 herein.

50

55



-5-

5  
10 The present invention also provides a method for  
expressing at least one Wnt-4AF and Wnt-5C homolog  
polypeptide in a recombinant host cell, comprising culturing  
a recombinant host cell as described herein under conditions  
15 wherein at least one Wnt-4AF and Wnt-5C homolog polypeptide  
is expressed in detectable or recoverable amounts.

20 The present invention also provides an isolated Wnt-4AF  
and Wnt-5C homolog polypeptide produced by a recombinant,  
synthetic, and/or any suitable purification method as  
10 described herein and/or as known in the art.

25 The present invention also provides a Wnt-4AF and Wnt-  
5C homolog antibody or fragment, comprising a polyclonal  
and/or monoclonal antibody or fragment that specifically  
binds at least one epitope specific to at least one Wnt-4AF  
15 and Wnt-5C homolog polypeptide as described herein.

30 The present invention also provides a method for  
producing a Wnt-4AF and Wnt-5C homolog antibody or antibody  
fragment, comprising generating the antibody or fragment  
that binds at least one epitope that is specific to an  
35 isolated Wnt-4AF and Wnt-5C homolog polypeptide as described  
20 herein, the generating done by knowing recombinant,  
synthetic and/or hybridoma methods.

40 The present invention also provides a Wnt-4AF and Wnt-  
5C homolog antibody or fragment produced by a method as  
25 described herein or as known in the art.

45 The present invention also provides a method for  
identifying compounds that bind a Wnt-4AF and Wnt-5C homolog  
polypeptide, comprising  
50  
55

5

-6-

10

a) admixing at least one isolated Wnt-4AF and Wnt-5C homolog polypeptide as described herein with a test compound or composition; and

15

b) detecting at least one binding interaction between the polypeptide and the compound or composition, optionally further comprising detecting a change in biological activity, such as a reduction or increase.

20

#### DESCRIPTION OF THE INVENTION

25

30

35

The present invention provides isolated, recombinant and/or synthetic nucleic acid molecules comprising at least one polynucleotide encoding at least one Wnt-4AF and Wnt-5C homolog polypeptide comprising specific full length sequences, fragments and specified variants thereof, such polypeptides, and methods of making and using said nucleic acids and polypeptides thereof. A Wnt-4AF and Wnt-5C homolog polypeptide of the invention comprises at least one fragment, domain, and/or specified variant as a portion or fragment of a Wnt-4AF and Wnt-5C homolog protein as described herein.

40

#### Utility

45

50

The present invention also provides at least one utility by providing isolated nucleic acid comprising polynucleotides of sufficient length and complementarity to a Wnt-4AF and Wnt-5C homolog nucleic acid for use as probes or amplification primers in the detection, quantitation, or isolation of gene sequences or transcripts. For example, isolated nucleic acids of the present invention can be used as probes for detecting deficiencies in the level of mRNA, in

55

5

-7-

10

15

screens for detection of mutations in at least one Wnt-4AF and Wnt-5C homolog gene (e.g., substitutions, deletions, or additions), or for monitoring upregulation of expression of said gene, or changes in biological activity as described herein in screening assays of compounds, and/or for detection of any number of allelic variants (polymorphisms or isoforms) of the gene.

20

25

30

35

The isolated nucleic acids of the present invention can also be used for recombinant expression of Wnt-4AF and Wnt-5C homolog polypeptides, or for use as immunogens in the preparation and/or screening of antibodies. The isolated nucleic acids of the present invention can also be employed for use in sense or antisense suppression of one or more Wnt-4AF and Wnt-5C homolog genes or nucleic acids, in a host cell, or tissue *in vivo* or *in vitro*. Attachment of chemical agents which bind, intercalate, cleave and/or crosslink to the isolated nucleic acids of the present invention can also be used to modulate transcription or translation of at least one nucleic acid disclosed herein.

#### 20 Citations

40

45

50

All publications or patents cited herein are entirely incorporated herein by reference as they show the state of the art at the time of the present invention to provide description and enablement of the present invention.

25 Publications refer to scientific, patent publication or any other information available in any media format, including all recorded, electronic or printed formats. The following citations are entirely incorporated by reference: Ausubel, et al., ed., Current Protocols in Molecular Biology, Greene

55

5

-8-

10

15

Publishing, NY, NY (1987-1998); Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> Edition, Cold Spring Harbor, NY (1989); Harlow and Lane, Antibodies, a Laboratory Manual, Cold Spring Harbor, NY (1989); Colligan, et al., eds., Current Protocols in Immunology, Greene Publishing, NY (1994-1998).

#### Definitions

20

25

The following definitions of terms are intended to correspond to those as well known in the art. The following terms are therefore not limited to the definitions given, but are used according to the state of the art, as demonstrated by cited and/or contemporary publications or patents.

30

A "polynucleotide" comprises at least 10-20 nucleotides of a nucleic acid (RNA, DNA or combination thereof), provided by any means, such as synthetic, recombinant isolation or purification method steps.

35

40

45

50

The terms "complementary" or "complementarity" as used herein refer to the capacity of purine, pyrimidine, synthetic or modified nucleotides to associate by partial or complete complementarity through hydrogen or other bonding to form partial or complete double- or triple-stranded nucleic acid molecules. The following base pairs occur by complete complementarity: (i) guanine (G) and cytosine (C); (ii) adenine (A) and thymine (T); and adenine (A) and uracil (U). "Partial complementarity" refers to association of two or more bases by one or more hydrogen bonds or attraction that is less than the complete complementarity as described

55

-9-

above. Partial or complete complementarity can occur between any two nucleotides, including naturally occurring or modified bases, e.g., as listed in 37 CFR § 1.822. All such nucleotides are included in polynucleotides of the invention as described herein.

The term "fusion protein" denotes a hybrid protein molecule not found in nature comprising a translational fusion or enzymatic fusion in which two or more different proteins or fragments thereof are covalently linked on a single polypeptide chain. The term "polypeptide" also includes such fusion proteins.

"Host cell" refers to any eucaryotic, procaryotic, or fusion or other cell or pseudo cell or membrane-containing construct that is suitable for propagating and/or expressing an isolated nucleic acid that is introduced into a host cell by any suitable means known in the art (e.g., but not limited to, transformation or transfection, or the like), or induced to express an endogenous nucleic acid encoding a Wnt-4AF and Wnt-5C homolog polypeptide according to the present invention. The cell can be part of a tissue or organism, isolated in culture or in any other suitable form.

The term "hybridization" as used herein refers to a process in which a partially or completely single-stranded nucleic acid molecule joins with a complementary strand through nucleotide base pairing. Hybridization can occur under conditions of low, moderate or high stringency, with high stringency preferred. The degree of hybridization depends upon, for example, the degree of homology, the

-10-

stringency conditions, and the length of hybridizing strands as known in the art.

By "isolated" nucleic acid molecule(s) is intended a nucleic acid molecule, DNA, RNA, or both which has been removed from its native or naturally occurring environment. For example, recombinant nucleic acid molecules contained or generated in culture, a vector and/or a host cell are considered isolated for the purposes of the present invention. Further examples of isolated nucleic acid molecules include recombinant nucleic acid molecules maintained in heterologous host cells or purified (partially or substantially) nucleic acid molecules in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the nucleic acid molecules of the present invention. Isolated nucleic acid molecules according to the present invention further include such molecules produced synthetically, purified from or provided in cells containing such nucleic acids, where the nucleic acid exists in other than a naturally occurring form, quantitatively or qualitatively.

"Isolated" used in reference to at least one polypeptide of the invention describes a state of isolation such that the peptide or polypeptide is not in a naturally occurring form and/or has been purified to remove at least some portion of cellular or non-cellular molecules with which the protein is naturally associated. However, "isolated" may include the addition of other functional or structural polypeptides for a specific purpose, where the other peptide may occur naturally associated with at least

-11-

one polypeptide of the present invention, but for which the resulting compound or composition does not exist naturally.

A "nucleic acid probe," "oligonucleotide probe," or "probe" as used herein comprises at least one detectably labeled or unlabeled nucleic acid which hybridizes under specified hybridization conditions with at least one other nucleic acid. This term also refers to a single- or partially double-stranded nucleic acid, oligonucleotide or polynucleotide that will associate with a complementary or partially complementary target nucleic acid to form at least a partially double-stranded nucleic acid molecule. A nucleic acid probe may be an oligonucleotide or a nucleotide polymer. A probe can optionally contain a detectable moiety which may be attached to the end(s) of the probe or be internal to the sequence of the probe, termed a "detectable probe" or "detectable nucleic acid probe."

A "primer" is a nucleic acid fragment or oligonucleotide which functions as an initiating substrate for enzymatic or synthetic elongation of, for example, a nucleic acid molecule, e.g., using an amplification reaction, such as, but not limited to, a polymerase chain reaction (PCR), as known in the art.

The term "stringency" refers to hybridization conditions for nucleic acids in solution. High stringency conditions disfavor non-homologous base pairing. Low stringency conditions have much less of this effect. Stringency may be altered, for example, by changes in temperature and/or salt concentration, or other conditions, as well known in the art.

5

-12-

10

15

20

25

30

35

40

45

50

55

A non-limiting example of "high stringency" conditions includes, for example, (a) a temperature of about 42°C, a formamide concentration of about  $\leq 20\%$ , and a low salt (SSC) concentration, or, alternatively, a temperature of about 65°C, or less, and a low salt (SSPE) concentration; (b) hybridization in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C (See, e.g., Ausubel, et al., ed., Current Protocols in Molecular Biology, 1987-1998, Wiley Interscience, New York, at §2.10.3). "SSC" comprises a hybridization and wash solution. A stock 20X SSC solution contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0. "SSPE" comprises a hybridization and wash solution. A 1X SSPE solution contains 180 mM NaCl, 9mM Na<sub>2</sub>HPO<sub>4</sub>, 0.9 mM NaH<sub>2</sub>PO<sub>4</sub> and 1 mM EDTA, pH 7.4.

The term "vector" as used herein refers to a nucleic acid compound used for introducing exogenous or endogenous nucleic acid into host cells. A vector comprises a nucleotide sequence which may encode one or more polypeptide molecules. Plasmids, cosmids, viruses and bacteriophages, in a natural state or which have undergone recombinant engineering, are non-limiting examples of commonly used vectors to provide recombinant vectors comprising at least one desired isolated nucleic acid molecule.

#### 25 Nucleic Acid Molecules

Using the information provided herein, such as the nucleotide sequences encoding at least 90-100% of the contiguous amino acids of at least one of SEQ ID NOS:2, 4, 6 & 8, specified fragments or variants thereof, or a deposited



-13-

vector comprising at least one of these sequences, a nucleic acid molecule of the present invention encoding a Wnt-4AF and Wnt-5C homolog polypeptide can be obtained using well-known methods.

Nucleic acid molecules of the present invention can be in the form of RNA, such as mRNA, hnRNA, tRNA or any other form, or in the form of DNA, including, but not limited to, cDNA and genomic DNA obtained by cloning or produced synthetically, or any combination thereof. The DNA can be triple-stranded, double-stranded or single-stranded, or any combination thereof. Any portion of at least one strand of the DNA or RNA can be the coding strand, also known as the sense strand, or it can be the non-coding strand, also referred to as the anti-sense strand.

Isolated nucleic acid molecules of the present invention include nucleic acid molecules comprising an open reading frame (ORF) shown in at least one of SEQ ID NOS:1, 3, 5, & 7; nucleic acid molecules comprising the coding sequence for a Wnt-4AF and Wnt-5C homolog polypeptide; and nucleic acid molecules which comprise a nucleotide sequence substantially different from those described above but which, due to the degeneracy of the genetic code, still encode at least one Wnt-4AF and Wnt-5C homolog polypeptide as described herein. Of course, the genetic code is well known in the art. Thus, it would be routine for one skilled in the art to generate such degenerate nucleic acid variants that code for specific Wnt-4AF and Wnt-5C homolog polypeptides of the present invention. See, e.g., Ausubel,

-14-

et al., *supra*, and such nucleic acid variants are included in the present invention.

In another aspect, the invention provides isolated nucleic acid molecules encoding a Wnt-4AF and Wnt-5C homolog polypeptide having an amino acid sequence as encoded by the cDNA clone contained in the plasmid deposited as designated clone names \_\_\_\_\_ and ATCC Deposit Nos. \_\_\_\_\_, respectively, deposited on \_\_\_\_\_.

In a further embodiment, nucleic acid molecules are provided encoding the mature Wnt-4AF and Wnt-5C homolog polypeptide or the full-length Wnt-4AF and Wnt-5C homolog polypeptide lacking the N-terminal methionine. The invention also provides an isolated nucleic acid molecule having the nucleotide sequence shown in at least one of SEQ ID NOS:1, 3, 5, & 7, or the nucleotide sequence of the Wnt-4AF and Wnt-5C homolog cDNA or coding sequence contained in at least one of the above-described deposited clones listed herein, or a nucleic acid molecule having a sequence complementary thereto. Non-limiting examples of such coding sequences include, but are not limited to, bases 2-1054 of SEQ ID NO:1 or 63-1139 of SEQ ID NO:3. Such isolated molecules, particularly nucleic acid molecules, are useful as probes for gene mapping by *in situ* hybridization with chromosomes, and for detecting transcription, translation and/or expression of the Wnt-4AF and Wnt-5C homolog gene in human tissue, for instance, by Northern blot analysis for mRNA detection.

5

-15-

10

15

20

25

30

35

40

45

50

55

Unless otherwise indicated, all nucleotide sequences identified by sequencing a nucleic acid molecule herein can be or were identified using an automated nucleic acid sequencer, and all amino acid sequences of polypeptides encoded by nucleic acid molecules identified herein can be or were identified by codon correspondence or by translation of a nucleic acid sequence identified using method steps as described herein or as known in the art. Therefore, as is well known in the art that for any nucleic acid sequence identified by this automated approach, any nucleotide sequence identified herein may contain some errors which are reproducibly correctable by resequencing based upon an available or a deposited vector or host cell containing the nucleic acid molecule using well-known methods.

Nucleotide sequences identified by automation are typically at least about 95% to at least about 99.999% identical to the actual nucleotide sequence of the sequenced nucleic acid molecule. The actual sequence can be more precisely identified by other approaches including manual nucleic acid sequencing methods well known in the art. As is also known in the art, a single insertion or deletion in an identified nucleotide sequence compared to the actual sequence will cause a frame shift in translation of the nucleotide sequence such that the identified amino acid sequence encoded by an identified nucleotide sequence will be completely different from the amino acid sequence actually encoded by the sequenced nucleic acid molecule, beginning at the point of such an insertion or deletion.

5

-16-

**Nucleic Acid Fragments**

10

15

20

25

30

35

40

The present invention is further directed to fragments of the isolated nucleic acid molecules described herein. By a fragment of an isolated nucleic acid molecule is meant a molecule having at least 10 nucleotides of a nucleotide sequence of a deposited cDNA or a nucleotide sequence shown in at least one of SEQ ID NOS:1, 3, 5, & 7 and is intended to mean fragments at least about 10 nucleotides, and at least about 40 nucleotides in length, which are useful, *inter alia* as diagnostic probes and primers as described herein. Of course, larger fragments such as at least about 50, 100, 120, 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, and/or 4000 or more nucleotides in length, are also useful according to the present invention as are fragments corresponding to most, if not all, of the nucleotide sequence (or the deposited cDNA) as shown at least one of SEQ ID NOS:1, 3, 5, & 7. By a fragment at least 10 nucleotides in length, for example, is intended fragments which include 10 or more contiguous nucleotides from the nucleotide sequence of the deposited cDNA or the nucleotide sequence as shown in SEQ ID NOS:1, 3, 5, & 7 or consensus sequences thereof, as determined by methods known in the art.

45

50

Such nucleotide fragments are useful according to the present invention for screening DNA sequences that code for one or more fragments of a Wnt-4AF and Wnt-5C homolog polypeptide as described herein. Such screening, as a non-limiting example can include the use of so-called "DNA chips" for screening DNA sequences of the present invention

55

5

-17-

10

of varying lengths, as described, e.g., in U.S. Patent Nos.  
5,631,734, 5,624,711, 5,744,305, 5,770,456, 5,770,722,  
5,675,443, 5,695,940, 5,710,000, 5,733,729, which are  
entirely incorporated herein by reference.

15

20

25

30

35

40

5 As indicated, nucleic acid molecules of the present  
invention which comprise a nucleic acid encoding a Wnt-4AF  
and Wnt-5C homolog polypeptide can include, but are not  
limited to, those encoding the amino acid sequence of the  
mature polypeptide, by itself; the coding sequence for the  
mature polypeptide and additional sequences, such as the  
coding sequence of at least one signal leader or fusion  
peptide or of the mature polypeptide, with or without the  
aforementioned additional coding sequences, such as at least  
one intron, together with additional, non-coding sequences,  
including but not limited to, introns and non-coding 5' and  
3' sequences, such as the transcribed, non-translated  
sequences that play a role in transcription, mRNA  
processing, including splicing and polyadenylation signals  
(for example - ribosome binding and stability of mRNA); an  
additional coding sequence which codes for additional amino  
acids, such as those which provide additional  
functionalities. Thus, the sequence encoding a polypeptide  
can be fused to a marker sequence, such as a sequence  
encoding a peptide that facilitates purification of the  
fused polypeptide.

45

50

Preferred nucleic acid fragments of the present  
invention also include nucleic acid molecules encoding  
epitope-bearing portions of a Wnt-4AF and Wnt-5C homolog  
polypeptide.

55

-18-

**Oligonucleotide and Polynucleotide Probes and/or Primers**

In another aspect, the invention provides a polynucleotide (either DNA or RNA) that comprises at least about 20 nt, still more preferably at least about 30 nt, and even more preferably at least about 30-2000 nt of a nucleic acid molecule described herein. These are useful as diagnostic probes and primers as discussed above and in more detail below.

By a portion of a polynucleotide of "at least 10 nt in length," for example, is intended 10 or more contiguous nucleotides from the nucleotide sequence of the reference polynucleotide (e.g., at least one deposited nucleic acid or at least one nucleotide sequence as shown in at least one of SEQ ID NOS:1, 3, 5, & 7.

Of course, a polynucleotide which hybridizes only to a poly A sequence (such as the 3' terminal poly(A) of a Wnt-4AF and Wnt-5C homolog cDNA shown in at least one of SEQ ID NOS:1, 3, 5, & 7 or to a complementary stretch of T (or U) residues, would not be included in a probe of the invention, since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone).

The present invention also provides subsequences of full-length nucleic acids. Any number of subsequences can be obtained by reference to at least one of SEQ ID NOS:1, 3, 5, & 7 or a complementary sequence, and using primers which selectively amplify, under stringent conditions to: at least two sites to the polynucleotides of the present invention, or

5

-19-

10

15

20

25

30

to two sites within the nucleic acid which flank and comprise a polynucleotide of the present invention, or to a site within a polynucleotide of the present invention and a site within the nucleic acid which comprises it. A variety of methods for obtaining 5' and/or 3' ends is well known in the art. See, e.g., RACE (Rapid Amplification of Complementary Ends) as described in M. A. Frohman, PCR Protocols: A Guide to Methods and Applications, M. A. Innis, D. H. Gelfand, J. J. Sninsky, T. J. White, Eds., Academic Press, Inc., San Diego, CA, pp. 28-38 (1990); see also, U.S. Patent No. 5,470,722, and Ausubel, et al., Current Protocols in Molecular Biology, Unit 15.6, Eds., Greene Publishing and Wiley-Interscience, New York (1989-1998). Thus, the present invention provides Wnt-4AF and Wnt-5C homolog polynucleotides having the sequence of the Wnt-4AF and Wnt-5C homolog gene, nuclear transcript, cDNA, or complementary sequences and/or subsequences thereof.

35

40

45

50

Primer sequences can be obtained by reference to a contiguous subsequence of a polynucleotide of the present invention. Primers are chosen to selectively hybridize, under PCR amplification conditions, to a polynucleotide of the present invention in an amplification mixture comprising a genomic and/or cDNA library from the same species. Generally, the primers are complementary to a subsequence of the amplified nucleic acid. In some embodiments, the primers will be constructed to anneal at their 5' terminal ends to the codon encoding the carboxy or amino terminal amino acid residue (or the complements thereof) of the polynucleotides of the present invention. The primer length in nucleotides

55

-20-

is selected from the group of integers consisting of from at least 15 to 50. Thus, the primers can be at least 15, 18, 20, 25, 30, 40, or 50 nucleotides in length or any range or value therein. A non-annealing sequence at the 5' end of the primer (a "tail") can be added, for example, to introduce a cloning site at the terminal ends of the amplified DNA.

The amplification primers may optionally be elongated in the 3' direction with additional contiguous or complementary nucleotides from the polynucleotide sequences, such as at least one of SEQ ID NOS:1, 3, 5, & 7 from which they are derived. The number of nucleotides by which the primers can be elongated is selected from the group of integers consisting of from at least 1 to at least 25. Thus, for example, the primers can be elongated with an additional 1, 5, 10, or 15 nucleotides or any range or value therein. Those of skill will recognize that a lengthened primer sequence can be employed to increase specificity of binding (i.e., annealing) to a target sequence, or to add useful sequences, such as links or restriction sites.

The amplification products can be translated using expression systems well known to those of skill in the art and as discussed, *infra*. The resulting translation products can be confirmed as polypeptides of the present invention by, for example, assaying for the appropriate catalytic activity (e.g., specific activity and/or substrate specificity), or verifying the presence of one or more linear epitopes which are specific to a polypeptide of the present invention. Methods for protein synthesis from PCR derived templates are



5

-21-

10

known in the art and available commercially. See, e.g.,  
Amersham Life Sciences, Inc., Catalog '97, p. 354.

15

**5 Polynucleotides Which Selectively Hybridize to a  
Polynucleotide as Described Herein**

20

The present invention provides isolated nucleic acids  
that hybridize under selective hybridization conditions to a  
polynucleotide disclosed herein, e.g., SEQ ID NOS:1, 3, 5, &  
7. Thus, the polynucleotides of this embodiment can be used  
for isolating, detecting, and/or quantifying nucleic acids  
comprising such polynucleotides. For example,  
polynucleotides of the present invention can be used to  
identify, isolate, or amplify partial or full-length clones  
in a deposited library. In some embodiments, the  
polynucleotides are genomic or cDNA sequences isolated, or  
otherwise complementary to, a cDNA from a human or mammalian  
nucleic acid library.

35

Preferably, the cDNA library comprises at least 80%  
full-length sequences, preferably at least 85% or 90% full-  
length sequences, and more preferably at least 95% full-  
length sequences. The cDNA libraries can be normalized to  
increase the representation of rare sequences. Low  
stringency hybridization conditions are typically, but not  
exclusively, employed with sequences having a reduced  
sequence identity relative to complementary sequences.  
Moderate and high stringency conditions can optionally be  
employed for sequences of greater identity. Low stringency  
conditions allow selective hybridization of sequences having

50

55

5

-22-

10

about 70% sequence identity and can be employed to identify orthologous or paralogous sequences.

15

Optionally, polynucleotides of this invention will encode an epitope of a polypeptide encoded by the polynucleotides described herein. The polynucleotides of this invention embrace nucleic acid sequences which can be employed for selective hybridization to a polynucleotide encoding a polypeptide of the present invention.

20

25

30

35

40

45

50

Screening polypeptides for specific binding to antibodies or fragments can be conveniently achieved using peptide display libraries. This method involves the screening of large collections of peptides for individual members having the desired function or structure. Antibody screening of peptide display libraries is well known in the art. The displayed peptide sequences can be from 3 to 5000 or more amino acids in length, frequently from 5-100 amino acids long, and often from about 8 to 15 amino acids long. In addition to direct chemical synthetic methods for generating peptide libraries, several recombinant DNA methods have been described. One type involves the display of a peptide sequence on the surface of a bacteriophage or cell. Each bacteriophage or cell contains the nucleotide sequence encoding the particular displayed peptide sequence. Such methods are described in PCT Patent Publication Nos. 91/17271, 91/18980, 91/19818, and 93/08278. Other systems for generating libraries of peptides have aspects of both in vitro chemical synthesis and recombinant methods. See, PCT Patent Publication Nos. 92/05258, 92/14843, and 96/19256. See also, U.S. Patent Nos. 5,658,754; and 5,643,768. Peptide

55

5

-23-

10

display libraries, vector, and screening kits are commercially available from such suppliers as Invitrogen (Carlsbad, CA). (See, e.g., Ausubel, *supra*; or Sambrook, *supra*).

15

#### 5 Polynucleotides Complementary to the Polynucleotides

20

As indicated above, the present invention provides isolated nucleic acids comprising Wnt-4AF and Wnt-5C homolog polynucleotides, wherein the polynucleotides are complementary to the polynucleotides described herein, above.

25

10 As those of skill in the art will recognize, complementary sequences base-pair throughout the entirety of their length with such polynucleotides (i.e., have 100% sequence identity over their entire length). Complementary bases associate through hydrogen bonding in double-stranded nucleic acids.

30

15 For example, the following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil. (See, e.g., Ausubel, *supra*; or Sambrook, *supra*)

35

#### Construction of Nucleic Acids

40

20 The isolated nucleic acids of the present invention can be made using (a) standard recombinant methods, (b) synthetic techniques, (c) purification techniques, or combinations thereof, as well known in the art.

45

25 The nucleic acids may conveniently comprise sequences in addition to a polynucleotide of the present invention. For example, a multi-cloning site comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in isolation of the polynucleotide. Also, translatable sequences may be inserted to aid in the

50

55

5

-24-

10

isolation of the translated polynucleotide of the present invention. For example, a hexa-histidine marker sequence provides a convenient means to purify the proteins of the present invention. The nucleic acid of the present invention

5 - excluding the polynucleotide sequence - is optionally a vector, adapter, or linker for cloning and/or expression of a polynucleotide of the present invention.

15

20

Additional sequences may be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression, to aid in isolation of the polynucleotide, or to improve the introduction of the polynucleotide into a cell. Typically, the length of a nucleic acid of the present invention less the length of its polynucleotide of the present invention is less than 20 kilobase pairs, often less

15 than 15 kb, and frequently less than 10 kb. Use of cloning vectors, expression vectors, adapters, and linkers is well known in the art. (See, e.g., Ausubel, *supra*; or Sambrook, *supra*)

25

30

35

#### 20 **Recombinant Methods for Constructing Nucleic Acids**

40

The isolated nucleic acid compositions of this invention, such as RNA, cDNA, genomic DNA, or a hybrid thereof, can be obtained from biological sources using any number of cloning methodologies known to those of skill in the art. In some embodiments, oligonucleotide probes which

25 selectively hybridize, under stringent conditions, to the polynucleotides of the present invention are used to identify the desired sequence in a cDNA or genomic DNA library. While

45 isolation of RNA, and construction of cDNA and genomic

50

55

5

-25-

10

libraries is well known to those of ordinary skill in the art. (See, e.g., Ausubel, *supra*; or Sambrook, *supra*)

#### Nucleic Acid Screening and Isolation Methods

15

5 A cDNA or genomic library can be screened using a probe based upon the sequence of a polynucleotide of the present invention, such as those disclosed herein. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different organisms. 10 Those of skill in the art will appreciate that various degrees of stringency of hybridization can be employed in the assay; and either the hybridization or the wash medium can be stringent. As the conditions for hybridization become more stringent, there must be a greater degree of complementarity 15 between the probe and the target for duplex formation to occur. The degree of stringency can be controlled by temperature, ionic strength, pH and the presence of a partially denaturing solvent such as formamide. For example, 20 the stringency of hybridization is conveniently varied by changing the polarity of the reactant solution through, for example, manipulation of the concentration of formamide within the range of 0% to 50%. The degree of complementarity 25 (sequence identity) required for detectable binding will vary in accordance with the stringency of the hybridization medium and/or wash medium. The degree of complementarity will 30 optimally be 100%; however, it should be understood that minor sequence variations in the probes and primers may be compensated for by reducing the stringency of the 35 hybridization and/or wash medium. 40 45 50

55

5

-26-

10

Methods of amplification of RNA or DNA are well known in the art and can be used according to the present invention without undue experimentation, based on the teaching and guidance presented herein.

15

5 Known methods of DNA or RNA amplification include, but are not limited to, polymerase chain reaction (PCR) and related amplification processes (see, e.g., U.S. Patent Nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188, to Mullis, et al.; 4,795,699 and 4,921,794 to Tabor, et al; 5,142,033 to Innis; 5,122,464 to Wilson, et al.; 5,091,310 to Innis; 5,066,584 to Gyllensten, et al; 4,889,818 to Gelfand, et al; 4,994,370 to Silver, et al; 4,766,067 to Biswas; 4,656,134 to Ringold) and RNA mediated amplification which uses anti-sense RNA to the target sequence as a template for double-stranded DNA synthesis (U.S. Patent No. 5,130,238 to Malek, et al, with the tradename NASBA), the entire contents of which are herein incorporated by reference. (See, e.g., Ausubel, *supra*; or Sambrook, *supra*)

20

25

30

35

For instance, polymerase chain reaction (PCR) technology can be used to amplify the sequences of polynucleotides of the present invention and related genes directly from genomic DNA or cDNA libraries. PCR and other in vitro amplification methods may also be useful, for example, to clone nucleic acid sequences that code for proteins to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. Examples of techniques sufficient to direct persons of skill through in vitro amplification methods are found in Berger, Sambrook, and

40

45

50

55

5

-27-

10

15

20

25

30

35

40

45

50

55

Ausubel, as well as Mullis, et al., U.S. Patent No. 4,683,202 (1987); and Innis, et al., PCR Protocols A Guide to Methods and Applications, Eds., Academic Press Inc., San Diego, CA (1990). Commercially available kits for genomic PCR amplification are known in the art. See, e.g., Advantage-GC Genomic PCR Kit (Clontech). The T4 gene 32 protein (Boehringer Mannheim) can be used to improve yield of long PCR products.

#### 10 Synthetic Methods for Constructing Nucleic Acids

The isolated nucleic acids of the present invention can also be prepared by direct chemical synthesis by methods such as the phosphotriester method of Narang, et al., Meth. Enzymol. 68:90-99 (1979); the phosphodiester method of Brown, et al., Meth. Enzymol. 68:109-151 (1979); the diethylphosphoramidite method of Beaucage, et al., Tetra. Letts. 22:1859-1862 (1981); the solid phase phosphoramidite triester method described by Beaucage and Caruthers, Tetra. Letts. 22(20):1859-1862 (1981), e.g., using an automated synthesizer, e.g., as described in Needham-VanDevanter, et al., Nucleic Acids Res. 12:6159-6168 (1984); and the solid support method of U.S. Patent No. 4,458,066. Chemical synthesis generally produces a single-stranded oligonucleotide, which may be converted into double-stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template. One of skill in the art will recognize that while chemical synthesis of DNA can be limited to sequences

5

-28-

10

of about 100 or more bases, longer sequences may be obtained by the ligation of shorter sequences.

#### Recombinant Expression Cassettes

15

5 The present invention further provides recombinant expression cassettes comprising a nucleic acid of the present invention. A nucleic acid sequence of the present invention, for example a cDNA or a genomic sequence encoding a full-length polypeptide of the present invention, can be used to  
20 construct a recombinant expression cassette which can be introduced into at least one desired host cell. A  
25 recombinant expression cassette will typically comprise a polynucleotide of the present invention operably linked to transcriptional initiation regulatory sequences that will  
15 direct the transcription of the polynucleotide in the  
30 intended host cell.

35

Both heterologous and non-heterologous (i.e., endogenous) promoters can be employed to direct expression of the nucleic acids of the present invention. These promoters  
20 can also be used, for example, in recombinant expression cassettes to drive expression of antisense nucleic acids to reduce, increase, or alter Wnt-4AF and Wnt-5C homolog  
40 content and/or composition in a desired tissue.

40

45

In some embodiments, isolated nucleic acids which serve  
25 as promoter or enhancer elements can be introduced in the appropriate position (generally upstream) of a non-heterologous form of a polynucleotide of the present invention so as to up or down regulate expression of a  
50 polynucleotide of the present invention. For example,

50

55



5

-29-

10

endogenous promoters can be altered *in vivo* or *in vitro* by mutation, deletion and/or substitution.

15

A polynucleotide of the present invention can be expressed in either sense or anti-sense orientation as desired. It will be appreciated that control of gene expression in either sense or anti-sense orientation can have a direct impact on the observable characteristics.

20

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been shown to be an effective means by which to block the transcription of target genes.

25

A variety of cross-linking agents, alkylating agents and radical generating species as pendant groups on polynucleotides of the present invention can be used to bind, label, detect and/or cleave nucleic acids. Knorre, et al., *Biochimie* 67:785-789 (1985); Vlassov, et al., *Nucleic Acids Res.* 14:4065-4076 (1986); Iverson and Dervan, *J. Am. Chem. Soc.* 109:1241-1243 (1987); Meyer, et al., *J. Am. Chem. Soc.* 111:8517-8519 (1989); Lee, et al., *Biochemistry* 27:3197-3203 (1988); Home, et al., *J. Am. Chem. Soc.* 112:2435-2437 (1990); Webb and Matteucci, *J. Am. Chem. Soc.* 108:2764-2765 (1986); *Nucleic Acids Res.* 14:7661-7674 (1986); Feteritz, et al., *J. Am. Chem. Soc.* 113:4000 (1991). Various compounds to bind, detect, label, and/or cleave nucleic acids are known in the art. See, for example, U.S. Patent Nos. 5,543,507; 5,672,593; 5,484,908; 5,256,648; and 5,681,941, each entirely incorporated herein by reference.

40

45

50

55

5

-30-

**VECTORS AND HOST CELLS**

10

15

20

25

30

35

40

45

50

The present invention also relates to vectors that include isolated nucleic acid molecules of the present invention, host cells that are genetically engineered with the recombinant vectors, and the production of Wnt-4AF and Wnt-5C homolog polypeptides or fragments thereof by recombinant techniques, as is well known in the art. See, e.g., Sambrook, et al., 1989; Ausubel, et al., 1987-1998, each entirely incorporated herein by reference.

10

The polynucleotides can optionally be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it can be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

20

The DNA insert should be operatively linked to an appropriate promoter, such as the phage lambda PL promoter, the *E. coli* *lac*, *trp* and *tac* promoters, the SV40 early and late promoters and promoters of retroviral LTRs, or any other suitable promoter. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination and, in the transcribed region, a ribosome binding site for translation. The coding portion of the mature transcripts expressed by the constructs will preferably include a translation initiating at the beginning and a termination codon (e.g., UAA, UGA or UAG) appropriately positioned at the end of the mRNA to be

55

-31-

translated, with VAA and VAG preferred for mammalian or eukaryotic cell expression.

Expression vectors will preferably include at least one selectable marker. Such markers include, e.g.,

5 dihydrofolate reductase, ampicillin (G418), or neomycin  
15 resistance for eukaryotic cell culture, and tetracycline or  
ampicillin resistance genes for culturing in *E. coli* and  
other bacteria or prokaryotics. Representative examples of  
20 appropriate hosts include, but are not limited to, bacterial  
10 cells, such as *E. coli*, *Streptomyces* and *Salmonella*  
typhimurium cells; fungal cells, such as yeast cells; insect  
25 cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal  
cells such as CHO, COS and Bowes melanoma cells; and plant  
cells. Appropriate culture mediums and conditions for the  
15 above-described host cells are known in the art. Vectors  
30 preferred for use in bacteria include pQE70, pQE60 and pQE-  
9, available from Qiagen; pBS vectors, Phagescript vectors,  
Bluescript vectors, pNH8A, pNH16a, pNH18A, pNH46A, available  
35 from Stratagene; and ptrc99a, pKK223-3, pKK233-3, pDR540,  
20 pRIT5 available from Pharmacia. Preferred eucaryotic  
vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG  
40 available from Stratagene; and pSVK3, pBPV, pMSG and pSVL  
available from Pharmacia. Other suitable vectors will be  
readily apparent to the skilled artisan.

25 Introduction of a vector construct into a host cell can  
45 be effected by calcium phosphate transfection, DEAE-dextran  
mediated transfection, cationic lipid-mediated transfection,  
electroporation, transduction, infection or other methods.  
50 Such methods are described in many standard laboratory

5

-32-

10

manuals, such as Sambrook, supra, Chapters 1-4 and 16-18;  
Ausubel, supra, Chapters 1, 9, 13, 15, 16.

15

Polypeptide(s) of the present invention can be  
expressed in a modified form, such as a fusion protein, and  
can include not only secretion signals, but also additional  
heterologous functional regions. For instance, a region of  
additional amino acids, particularly charged amino acids,  
can be added to the N-terminus of a polypeptide to improve  
stability and persistence in the host cell, during  
purification, or during subsequent handling and storage.  
Also, peptide moieties can be added to a polypeptide to  
facilitate purification. Such regions can be removed prior  
to final preparation of a polypeptide. Such methods are  
described in many standard laboratory manuals, such as  
Sambrook, supra, Chapters 17.29-17.42 and 18.1-18.74;  
Ausubel, supra, Chapters 16, 17 and 18.

25

30

#### **Expression of Proteins in Host Cells**

35

Using nucleic acids of the present invention, one may  
express a protein of the present invention in a recombinantly  
engineered cell, such as bacteria, yeast, insect, or  
mammalian cells. The cells produce the protein in a non-  
natural condition (e.g., in quantity, composition, location,  
and/or time), because they have been genetically altered  
through human intervention to do so.

40

45

It is expected that those of skill in the art are  
knowledgeable in the numerous expression systems available  
for expression of a nucleic acid encoding a protein of the  
present invention. No attempt to describe in detail the

50

55

-33-

various methods known for the expression of proteins in prokaryotes or eukaryotes will be made.

In brief summary, the expression of isolated nucleic acids encoding a protein of the present invention will typically be achieved by operably linking, for example, the DNA or cDNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector. The vectors can be suitable for replication and integration in either prokaryotes or eukaryotes. Typical expression vectors contain transcription and translation terminators, initiation sequences and promoters useful for regulation of the expression of the DNA encoding a protein of the present invention. To obtain high level expression of a cloned gene, it is desirable to construct expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator. One of skill would recognize that modifications can be made to a protein of the present invention without diminishing its biological activity. Some modifications may be made to facilitate the cloning, expression, or incorporation of the targeting molecule into a fusion protein. Such modifications are well known to those of skill in the art and include, for example, a methionine added at the amino terminus to provide an initiation site, or additional amino acids (e.g., poly His) placed on either terminus to create conveniently located restriction sites or termination codons or purification sequences.

5

-34-

10

15

Alternatively, nucleic acids of the present invention can be expressed in a host cell by turning on (by manipulation) in a host cell that contains endogenous DNA encoding a polypeptide of the present invention. Such methods are well known in the art, e.g., as described in US patent Nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761, entirely incorporated herein by reference.

20

#### **Expression in Prokaryotes**

10

Prokaryotic cells may be used as hosts for expression. Prokaryotes most frequently are represented by various strains of *E. coli*; however, other microbial strains may also be used. Commonly used prokaryotic control sequences which are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta lactamase (penicillinase) and lactose (*lac*) promoter systems (Chang, et al., *Nature* 198:1056 (1977)), the tryptophan (*trp*) promoter system (Goeddel, et al., *Nucleic Acids Res.* 8:4057 (1980)) and the lambda derived P<sub>L</sub> promoter and N-gene ribosome binding site (Shimatake, et al., *Nature* 292:128 (1981)). The inclusion of selection markers in DNA vectors transfected in *E. coli* is also useful. Examples of such markers include genes specifying resistance to

30

35

20

40

25

45

The vector is selected to allow introduction into the appropriate host cell. Bacterial vectors are typically of plasmid or phage origin. Appropriate bacterial cells are infected with phage vector particles or transfected with

50

55

-35-

naked phage vector DNA. If a plasmid vector is used, the bacterial cells are transformed with the plasmid vector DNA.

Expression systems for expressing a protein of the present invention are available using *Bacillus* sp. and *Salmonella* (Palva, et al., *Gene* 22:229-235 (1983); Mosbach, et al., *Nature* 302:543-545 (1983)).

#### **Expression in Eukaryotes**

A variety of eukaryotic expression systems such as yeast, insect cell lines, plant and mammalian cells, are known to those of skill in the art. As explained briefly below, a nucleic acid of the present invention can be expressed in these eukaryotic systems.

Synthesis of heterologous proteins in yeast is well known. F. Sherman, et al., *Methods in Yeast Genetics*, Cold Spring Harbor Laboratory (1982) is a well-recognized work describing the various methods available to produce the protein in yeast. Two widely utilized yeast for production of eukaryotic proteins are *Saccharomyces cerevisiae* and *Pichia pastoris*. Vectors, strains, and protocols for expression in *Saccharomyces* and *Pichia* are known in the art and available from commercial suppliers (e.g., Invitrogen). Suitable vectors usually have expression control sequences, such as promoters, including 3-phosphoglycerate kinase or alcohol oxidase, and an origin of replication, termination sequences and the like as desired.

A protein of the present invention, once expressed, can be isolated from yeast by lysing the cells and applying standard protein isolation techniques to the lysates. The

5

-36-

10

monitoring of the purification process can be accomplished by using Western blot techniques or radioimmunoassay of other standard immunoassay techniques.

15

The sequences encoding proteins of the present invention can also be ligated to various expression vectors for use in transfecting cell cultures of, for instance, mammalian, insect, or plant origin. Illustrative of cell cultures useful for the production of the peptides are mammalian cells. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may also be used. A number of suitable host cell lines capable of expressing intact proteins have been developed in the art, and include the HEK293, BHK21, and CHO cell lines.

25

30

Expression vectors for these cells can include expression control sequences, such as an origin of replication, a promoter (e.g., the CMV promoter, a HSV tk promoter or pgk (phosphoglycerate kinase) promoter), an enhancer (Queen, et al., Immunol. Rev. 89:49 (1986)), and processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., an SV40 large T Ag poly A addition site), and transcriptional terminator sequences.

35

40

Other animal cells useful for production of proteins of the present invention are available, for instance, from the American Type Culture Collection Catalogue of Cell Lines and Hybridomas (7th edition, 1992).

45

50

Appropriate vectors for expressing proteins of the present invention in insect cells are usually derived from the SF9 baculovirus. Suitable insect cell lines include mosquito larvae, silkworm, armyworm, moth and Drosophila cell

55



-37-

lines such as a Schneider cell line (See Schneider, J. Embryol. Exp. Morphol. 27:353-365 (1987)).

As with yeast, when higher animal or plant host cells are employed, polyadenylation or transcription terminator sequences are typically incorporated into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, et al., J. Virol. 45:773-781 (1983)).

Additionally, gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. M. Saveria-Campo, Bovine Papilloma Virus DNA, a Eukaryotic Cloning Vector in DNA Cloning Vol. II, a Practical Approach, D. M. Glover, Ed., IRL Press, Arlington, VA, pp. 213-238 (1985).

#### Protein Purification

A Wnt-4AF and Wnt-5C homolog polypeptide can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography ("HPLC") is employed for purification. Polypeptides of the present invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from a prokaryotic or

-38-

5  
10 eucaryotic host, including, for example, bacterial, yeast,  
higher plant, insect and mammalian cells. Depending upon  
the host employed in a recombinant production procedure, the  
15 polypeptides of the present invention can be glycosylated or  
5 can be non-glycosylated. In addition, polypeptides of the  
invention can also include an initial modified methionine  
residue, in some cases as a result of host-mediated  
processes. Such methods are described in many standard  
20 laboratory manuals, such as Sambrook, supra, Chapters 17.37-  
10 17.42; Ausubel, supra, Chapters 10, 12, 13, 16, 18 and 20.

25 **Wnt-4AF AND Wnt-5C HOMOLOG POLYPEPTIDES AND FRAGMENTS AND  
VARIANTS**

The invention further provides an isolated Wnt-4AF and  
Wnt-5C homolog polypeptides having fragments or specified  
30 15 variants of the amino acid sequence encoded by the deposited  
cDNAs, or the amino acid sequence in SEQ ID NOS:2, 4, 6 & 8.

35 The isolated proteins of the present invention comprise  
a polypeptide encoded by any one of the polynucleotides of  
the present invention as discussed more fully, supra, or  
20 polypeptides which are specified fragments or variants  
thereof.

40 Exemplary polypeptide sequences are provided in SEQ ID  
NOS:2, 4, 6 & 8. The proteins of the present invention or  
variants thereof can comprise any number of contiguous amino  
45 25 acid residues from a polypeptide of the present invention,  
wherein that number is selected from the group of integers  
consisting of from 90-100% of the number of contiguous  
residues in a full-length Wnt-4AF and Wnt-5C homolog  
50 polypeptide. Optionally, this subsequence of contiguous

5

-39-

10

amino acids is at least 50, 60, 70, 80, or 90 amino acids in length. Further, the number of such subsequences can be any integer selected from the group consisting of from 1 to 20, such as 2, 3, 4, or 5.

15

5 As those of skill will appreciate, the present invention includes biologically active polypeptides of the present invention (i.e., enzymes). Biologically active polypeptides have a specific activity at least 20%, 30%, or 40%, and preferably at least 50%, 60%, or 70%, and most preferably at 10 least 80%, 90%, or 95%-1000% of that of the native (non-synthetic), endogenous polypeptide. Further, the substrate specificity (e.g.,  $k_{cat}/K_m$ ) is optionally substantially 25 similar to the native (non-synthetic), endogenous polypeptide. Typically, the  $K_m$  will be at least 30%, 40%, or 15 50%, that of the native (non-synthetic), endogenous 30 polypeptide; and more preferably at least 60%, 70%, 80%, or 90%-1000%. Methods of assaying and quantifying measures of enzymatic activity and substrate specificity, are well known 35 to those of skill in the art.

30

35

40

20 Generally, the polypeptides of the present invention will, when presented as an immunogen, elicit production of an antibody specifically reactive to a polypeptide of the 40 present invention encoded by a polynucleotide of the present invention as described, supra. Exemplary polypeptides 25 include those which are full-length, such as those disclosed herein. Further, the proteins of the present invention will 45 not bind to antisera raised against a polypeptide of the present invention which has been fully immunosorbed with the 50 same polypeptide. Immunoassays for determining binding are

45

50

55

5

-40-

10

well known to those of skill in the art. A preferred immunoassay is a competitive immunoassay as discussed, infra.

15

Thus, the proteins of the present invention can be employed as immunogens for constructing antibodies immunoreactive to a protein of the present invention for such exemplary utilities as immunoassays or protein purification techniques.

20

A Wnt-4AF and Wnt-5C homolog polypeptide of the present invention can include one or more amino acid substitutions, deletions or additions, either from natural mutations or human manipulation, as specified herein.

25

Of course, the number of amino acid substitutions a skilled artisan would make depends on many factors, including those described above. Generally speaking, the number of amino acid substitutions, insertions or deletions for any given Wnt-4AF and Wnt-5C homolog polypeptide will not be more than 40, 30, 20, 10, 5, or 3, such as 1-30 or any range or value therein, as specified herein.

30

35

Amino acids in a Wnt-4AF and Wnt-5C homolog polypeptide of the present invention that are essential for function can be identified by methods known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis

40

(Cunningham and Wells, Science 244:1081-1085 (1989)). The latter procedure introduces single alanine mutations at every residue in the molecule. The resulting mutant

45

molecules are then tested for biological activity. Sites that are critical for ligand-protein binding can also be identified by structural analysis such as crystallization, nuclear magnetic resonance or photoaffinity labeling (Smith,

50

55

-41-

et al., J. Mol. Biol. 224:899-904 (1992) and de Vos, et al.,  
Science 255:306-312 (1992)).

Wnt-4AF and Wnt-5C homolog polypeptides of the present  
invention can include but are not limited to, at least one  
selected from extracellular, intracellular, transmembrane,  
or active, respectively, of SEQ ID NOS:2, 4, 6 & 8.

A Wnt-4AF and Wnt-5C homolog polypeptide can further  
comprise a polypeptide of at least one of 359 contiguous  
amino acids of SEQ ID NOS:2, 4, 6 & 8.

A Wnt-4AF and Wnt-5C homolog polypeptide further  
includes an amino acid sequence selected from one or more of  
SEQ ID NOS:2, 4, 6 & 8.

Non-limiting mutants that can enhance or maintain at  
least one of the listed activities include, but are not  
limited to, any of the above polypeptides, further  
comprising at least one mutation corresponding to at least  
one substitution of SEQ ID NOS:2, 4, 6 & 8.

**Antigenic/Epitope Comprising Wnt-4AF and Wnt-5C Homolog  
Peptide and Polypeptides**

In another aspect, the invention provides a peptide or  
polypeptide comprising an epitope-bearing portion of a  
polypeptide of the invention according to methods well known  
in the art. See, e.g., Colligan, et al., ed., Current  
Protocols in Immunology, Greene Publishing, NY (1993-1998),  
Ausubel, supra, each entirely incorporated herein by  
reference.

The epitope of this polypeptide portion is an  
immunogenic or antigenic epitope of a polypeptide described  
herein. An "immunogenic epitope" can be defined as a part

5

-42-

10

15

of a polypeptide that elicits an antibody response when the whole polypeptide is the immunogen. On the other hand, a region of a polypeptide molecule to which an antibody can bind is defined as an "antigenic epitope." The number of immunogenic epitopes of a polypeptide generally is less than the number of antigenic epitopes. See, for instance, Geysen, et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1983).

20

25

30

As to the selection of peptides or polypeptides bearing an antigenic epitope (i.e., that contain at least a portion of a region of a polypeptide molecule to which an antibody can bind), it is well known in the art that relatively short synthetic peptides that mimic part of a polypeptide sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked polypeptide. See, for instance, J. G. Sutcliffe, et al., "Antibodies that react with preidentified sites on polypeptides," Science 219:660-666 (1983).

35

40

45

50

Antigenic epitope-bearing peptides and polypeptides of the invention are useful to raise antibodies, including monoclonal antibodies, or screen antibodies, including fragments or single chain antibodies, that bind specifically to a polypeptide of the invention. See, for instance, Wilson, et al., Cell 37:767-778 (1984) at 777. Antigenic epitope-bearing peptides and polypeptides of the invention preferably contain a sequence of at least five, more preferably at least nine, and most preferably between at least about 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention.

55

5

-43-

10

15

20

25

30

35

40

45

50

55

The epitope-bearing peptides and polypeptides of the invention can be produced by any conventional means. R. A. Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids," Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985). This "Simultaneous Multiple Peptide Synthesis (SMPS)" process is further described in U.S. Patent No. 4,631,211 to Houghten, et al. (1986).

As one of skill in the art will appreciate, Wnt-4AF and Wnt-5C homolog polypeptides of the present invention and the epitope-bearing fragments thereof described above can be combined with parts of the constant domain of immunoglobulins (IgG), resulting in chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. This has been shown, e.g., for chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins (EPA 394,827; Traunecker, et al., Nature 331:84-86 (1988)). Fusion proteins that have a disulfide-linked dimeric structure due to the IgG part can also be more efficient in binding and neutralizing other molecules than the monomeric Wnt-4AF and Wnt-5C homolog polypeptide or polypeptide fragment alone (Fountoulakis, et al., J. Biochem. 270:3958-3964 (1995)).

5

-44-

### Production of Antibodies

10

15

20

25

The polypeptides of this invention and fragments thereof may be used in the production of antibodies. The term "antibody" as used herein describes antibodies, fragments of antibodies (such as, but not limited, to Fab, Fab', Fab2', and Fv fragments), and modified versions thereof, as well known in the art (e.g., chimeric, humanized, recombinant, veneered, resurfaced or CDR-grafted) such antibodies are capable of binding antigens of a similar nature as the parent antibody molecule from which they are derived. The instant invention also encompasses single chain polypeptide binding molecules.

30

The production of antibodies, both monoclonal and polyclonal, in animals is well known in the art. See, e.g., Colligan, *supra*, entirely incorporated herein by reference.

35

40

45

Single chain antibodies and libraries thereof are yet another variety of genetically engineered antibody technology that is well known in the art. (See, e.g., R. E. Bird, et al., *Science* 242:423-426 (1988); PCT Publication Nos. WO 88/01649, WO 90/14430, and WO 91/10737. Single chain antibody technology involves covalently joining the binding regions of heavy and light chains to generate a single polypeptide chain. The binding specificity of the intact antibody molecule is thereby reproduced on a single polypeptide chain.

50

Antibodies included in this invention are useful in diagnostics, therapeutics or in diagnostic/therapeutic combinations.

55



5

-45-

10

15

20

25

30

35

40

45

50

55

The polypeptides of this invention or suitable fragments thereof can be used to generate polyclonal or monoclonal antibodies, and various inter-species hybrids, or humanized antibodies, or antibody fragments, or single-chain antibodies. The techniques for producing antibodies are well known to skilled artisans. (See, e.g., Colligan supra; Monoclonal Antibodies: Principles & Applications, Ed. J. R. Birch & E. S. Lennox, Wiley-Liss (1995)).

A polypeptide used as an immunogen may be modified or administered in an adjuvant, by subcutaneous or intraperitoneal injection into, for example, a mouse or a rabbit. For the production of monoclonal antibodies, spleen cells from immunized animals are removed, fused with myeloma or other suitable known cells, and allowed to become monoclonal antibody producing hybridoma cells in the manner known to the skilled artisan. Hybridomas that secrete a desired antibody molecule can be screened by a variety of well known methods, for example ELISA assay, Western blot analysis, or radioimmunoassay (Lutz, et al. Exp. Cell Res. 175:109-124 (1988); Monoclonal Antibodies: Principles & Applications, Ed. J. R. Birch & E. S. Lennox, Wiley-Liss (1995); Colligan, supra).

For some applications labeled antibodies are desirable. Procedures for labeling antibody molecules are widely known, including for example, the use of radioisotopes, affinity labels, such as biotin or avidin, enzymatic labels, for example horseradish peroxidase, and fluorescent labels, such as FITC or rhodamine (See, e.g., Colligan, supra).

-46-

Labeled antibodies are useful for a variety of diagnostic applications. In one embodiment the present invention relates to the use of labeled antibodies to detect the presence of a Wnt-4AF and Wnt-5C homolog polypeptide.

Alternatively, the antibodies could be used in a screen to identify potential modulators of a Wnt-4AF and Wnt-5C homolog polypeptide. For example, in a competitive displacement assay, the antibody or compound to be tested is labeled by any suitable method. Competitive displacement of an antibody from an antibody-antigen complex by a test compound such that a test compound-antigen complex is formed provides a method for identifying compounds that bind HPLFP.

#### **Transgenics and Chimeric Non-Human Mammals**

The present invention is also directed to a transgenic non-human eukaryotic animal (preferably a rodent, such as a mouse) the germ cells and somatic cells of which contain nucleic acid genomic DNA according to the present invention which codes for at least one Wnt-4AF and Wnt-5C homolog polypeptide. At least one Wnt-4AF and Wnt-5C homolog nucleic acid can be introduced into the animal to be made transgenic, or an ancestor of the animal, at an embryonic stage, preferably the 1-1000 cell or oocyte, stage, and preferably not later than about the 64-cell stage. The term "transgene," as used herein, means a gene which is incorporated into the genome of the animal and is expressed in the animal, resulting in the presence of at least one Wnt-4AF and Wnt-5C homolog polypeptide in the transgenic animal.

5

-47-

10

There are several means by which such a Wnt-4AF and Wnt-5C homolog nucleic acid can be introduced into a cell or genome of the animal embryo so as to be chromosomally incorporated and expressed according to known methods.

15

5 Chimeric non-human mammals in which fewer than all of the somatic and germ cells contain the a Wnt-4AF and Wnt-5C homolog polypeptide nucleic acid of the present invention, such as animals produced when fewer than all of the cells of the morula are transfected in the process of producing the transgenic animal, are also intended to be within the scope of the present invention.

20

25

Chimeric non-human mammals having human cells or tissue engrafted therein are also encompassed by the present invention, which may be used for testing expression of at

30

15 least one Wnt-4AF and Wnt-5C homolog polypeptide in human tissue and/or for testing the effectiveness of therapeutic and/or diagnostic agents associated with delivery vectors which preferentially bind to a Wnt-4AF and Wnt-5C homolog

35

polypeptide of the present invention. Methods for providing chimeric non-human mammals are provided, e.g., in U.S. Serial Nos. 07/508,225, 07/518,748, 07/529,217, 07/562,746,

40

07/596,518, 07/574,748, 07/575,962, 07/207,273, 07/241,590 and 07/137,173, which are entirely incorporated herein by reference, for their description of how to engraft human

45

25 cells or tissue into non-human mammals. The techniques described in Leder, U.S. Patent No. 4,736,866 (hereby entirely incorporated by reference) for producing transgenic non-human mammals may be used for the production of a transgenic non-human mammal of the present

50

55

5

-48-

10

invention. The various techniques described in U.S. patent Nos. 5,454,807, 5,073,490, 5,347,075 and 4,736,866, the entire contents of which are hereby incorporated by reference, may also be used.

15

5       Animals carrying at least one Wnt-4AF and Wnt-5C homolog polypeptide and/or nucleic acid can be used to test compounds or other treatment modalities which may prevent, suppress or cure a pathology relating to at least one Wnt-4AF and Wnt-5C homolog polypeptide or Wnt-4AF and Wnt-5C homolog nucleic acid. Such transgenic animals will also serve as a model for testing of diagnostic methods for the same diseases.

20

25

Transgenic animals according to the present invention can also be used as a source of cells for cell culture.

30

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

35

**Example 1: Expression and Purification of a Wnt-4AF and Wnt-5C Homolog Polypeptide in E. coli**

20

40

The bacterial expression vector pQE60 is used for bacterial expression in this example. (QIAGEN, Inc., Chatsworth, CA). pQE60 encodes ampicillin antibiotic resistance ("Ampr") and contains a bacterial origin of replication ("ori"), an IPTG inducible promoter, a ribosome binding site ("RBS"), six codons encoding histidine residues that allow affinity purification using nickel-nitrilo-triacetic acid ("Ni-NTA") affinity resin sold by QIAGEN, Inc., and suitable single restriction enzyme cleavage sites.

45

50

55

5

-49-

10

15

These elements are arranged such that a DNA fragment encoding a polypeptide can be inserted in such a way as to produce that polypeptide with the six His residues (i.e., a "6 X His tag") covalently linked to the carboxyl terminus of that polypeptide. However, a polypeptide coding sequence can optionally be inserted such that translation of the six His codons is prevented and, therefore, a polypeptide is produced with no 6 X His tag.

20

25

30

35

40

45

50

55

The nucleic acid sequence encoding the desired portion of a Wnt-4AF and Wnt-5C homolog polypeptide lacking the hydrophobic leader sequence is amplified from the deposited cDNA clone using PCR oligonucleotide primers (based on the sequences presented, e.g., as presented in at least one of SEQ ID NOS:1, 3, 5, & 7, which anneal to the amino terminal encoding DNA sequences of the desired portion of a Wnt-4AF and Wnt-5C homolog polypeptide and to sequences in the deposited construct 3' to the cDNA coding sequence. Additional nucleotides containing restriction sites to facilitate cloning in the pQE60 vector are added to the 5' and 3' sequences, respectively.

For cloning a Wnt-4AF and Wnt-5C homolog polypeptide, the 5' and 3' primers have nucleotides corresponding or complementary to a portion of the coding sequence of a Wnt-4AF and Wnt-5C homolog, e.g., as presented in at least one of SEQ ID NOS:1, 3, 5, & 7 according to known method steps.

One of ordinary skill in the art would appreciate, of course, that the point in a polypeptide coding sequence where the 5' primer begins can be varied to amplify a

5

-50-

10

desired portion of the complete polypeptide shorter or longer than the mature form.

15

The amplified Wnt-4AF and Wnt-5C homolog nucleic acid fragments and the vector pQE60 are digested with appropriate restriction enzymes and the digested DNAs are then ligated together. Insertion of the Wnt-4AF and Wnt-5C homolog DNA into the restricted pQE60 vector places a Wnt-4AF and Wnt-5C homolog polypeptide coding region including its associated stop codon downstream from the IPTG-inducible promoter and in-frame with an initiating AUG codon. The associated stop codon prevents translation of the six histidine codons downstream of the insertion point.

25

30

The ligation mixture is transformed into competent *E. coli* cells using standard procedures such as those described in Sambrook, et al., 1989; Ausubel, 1987-1998. *E. coli* strain M15/rep4, containing multiple copies of the plasmid pREP4, which expresses the lac repressor and confers kanamycin resistance ("Kanr"), is used in carrying out the illustrative example described herein. This strain, which is only one of many that are suitable for expressing Wnt-4AF and Wnt-5C homolog polypeptide, is available commercially from QIAGEN, Inc. Transformants are identified by their ability to grow on LB plates in the presence of ampicillin and kanamycin. Plasmid DNA is isolated from resistant colonies and the identity of the cloned DNA confirmed by restriction analysis, PCR and DNA sequencing.

35

40

45

50

Clones containing the desired constructs are grown overnight ("O/N") in liquid culture in LB media supplemented with both ampicillin (100 µg/ml) and kanamycin (25 µg/ml).

55

5

-51-

10

15

20

25

30

35

40

45

50

The O/N culture is used to inoculate a large culture, at a dilution of approximately 1:25 to 1:250. The cells are grown to an optical density at 600 nm ("OD600") of between 0.4 and 0.6. Isopropyl-b-D-thiogalactopyranoside ("IPTG") is then added to a final concentration of 1 mM to induce transcription from the lac repressor sensitive promoter, by inactivating the lacI repressor. Cells subsequently are incubated further for 3 to 4 hours. Cells then are harvested by centrifugation.

10 The cells are then stirred for 3-4 hours at 4°C in 6M guanidine-HCl, pH8. The cell debris is removed by centrifugation, and the supernatant containing the Wnt-4AF and Wnt-5C homolog is dialyzed against 50 mM Na-acetate buffer pH6, supplemented with 200 mM NaCl. Alternatively, a  
15 polypeptide can be successfully refolded by dialyzing it against 500 mM NaCl, 20% glycerol, 25 mM Tris/HCl pH7.4, containing protease inhibitors.

If insoluble protein is generated, the protein is made soluble according to known method steps. After renaturation  
20 the polypeptide is purified by ion exchange, hydrophobic interaction and size exclusion chromatography.

Alternatively, an affinity chromatography step such as an  
40 antibody column is used to obtain pure Wnt-4AF and Wnt-5C homolog polypeptide. The purified polypeptide is stored at  
25 4°C or frozen at -40°C to -120°C.

**Example 2: Cloning and Expression of a Wnt-4AF and Wnt-5C Homolog Polypeptide in a Baculovirus Expression System**

In this illustrative example, the plasmid shuttle  
50 vector pA2 GP is used to insert the cloned DNA encoding the

55

5

-52-

10

15

20

25

30

35

mature polypeptide into a baculovirus to express a Wnt-4AF and Wnt-5C homolog polypeptide, using a baculovirus leader and standard methods as described in Summers, et al., A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agricultural Experimental Station Bulletin No. 1555 (1987). This expression vector contains the strong polyhedrin promoter of the Autographa californica nuclear polyhedrosis virus (AcMNPV) followed by the secretory signal peptide (leader) of the baculovirus gp67 polypeptide and convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from E. coli under control of a weak Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate viable virus that expresses the cloned polynucleotide.

40

45

Other baculovirus vectors are used in place of the vector above, such as pAc373, pVL941 and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow, et al., Virology 170:31-39.

50

55



5

-53-

5           The cDNA sequence encoding the mature Wnt-4AF and Wnt-  
10       5C homolog polypeptide in the deposited or other clone,  
      lacking the AUG initiation codon and the naturally  
      associated nucleotide binding site, is amplified using PCR  
15       5   oligonucleotide primers corresponding to the 5' and 3'  
      sequences of the gene. Non-limiting examples include 5' and  
      3' primers having nucleotides corresponding or complementary  
      to a portion of the coding sequence of a Wnt-4AF and Wnt-5C  
20       homolog polypeptide, e.g., as presented in at least one of  
10       SEQ ID NOS:1, 3, 5, & 7 according to known method steps.

      The amplified fragment is isolated from a 1% agarose  
25       gel using a commercially available kit (e.g., "Geneclean,"  
      BIO 101 Inc., La Jolla, CA). The fragment then is then  
      digested with the appropriate restriction enzyme and again  
15       is purified on a 1% agarose gel. This fragment is  
30       designated herein "F1".

      The plasmid is digested with the corresponding  
      restriction enzymes and optionally, can be dephosphorylated  
35       using calf intestinal phosphatase, using routine procedures  
20       known in the art. The DNA is then isolated from a 1%  
      agarose gel using a commercially available kit ("Geneclean"  
40       BIO 101 Inc., La Jolla, CA). This vector DNA is designated  
      herein "V1".

      Fragment F1 and the dephosphorylated plasmid V1 are  
25       ligated together with T4 DNA ligase. E. coli HB101 or other  
45       suitable E. coli hosts such as XL-1 Blue (Stratagene Cloning  
      Systems, La Jolla, CA) cells are transformed with the  
      ligation mixture and spread on culture plates. Bacteria are  
50       identified that contain the plasmid with the human Wnt-4AF

55

5

-54-

10

15

and Wnt-5C homolog gene using the PCR method, in which one of the primers that is used to amplify the gene and the second primer is from well within the vector so that only those bacterial colonies containing the Wnt-4AF and Wnt-5C homolog gene fragment will show amplification of the DNA. The sequence of the cloned fragment is confirmed by DNA sequencing. This plasmid is designated herein pBac Wnt-4AF and Wnt-5C homolog .

20

10

25

30

35

40

45

50

Five µg of the plasmid pBacWnt-4AF and Wnt-5C homolog is co-transfected with 1.0 µg of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner, et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). 1 µg of BaculoGold™ virus DNA and 5 µg of the plasmid pBac Wnt-4AF and Wnt-5C homolog are mixed in a sterile well of a microtiter plate containing 50 µl of serum-free Grace's medium (Life Technologies, Inc., Rockville, MD). Afterwards, 10 µl Lipofectin plus 90 µl Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is rocked back and forth to mix the newly added solution. The plate is then incubated for 5 hours at 27°C. After 5 hours the transfection solution is removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. The plate is put back into an incubator and cultivation is continued at 27°C for four days.

55

5

-55-

10

15

20

25

30

35

40

45

50

55

After four days the supernatant is collected and a plaque assay is performed, according to known methods. An agarose gel with "Blue Gal" (Life Technologies, Inc., Rockville, MD) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies, Inc., Rockville, MD, page 9-10). After appropriate incubation, blue stained plaques are picked with a micropipettor tip (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200  $\mu$ l of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4°C. The recombinant virus is called V-Wnt-4AF and Wnt-5C homolog.

To verify the expression of the Wnt-4AF and Wnt-5C homolog gene, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus V-Wnt-4AF and Wnt-5C homolog at a multiplicity of infection ("MOI") of about 2. Six hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available, e.g., from Life Technologies, Inc., Rockville, MD). If radiolabeled polypeptides are desired, 42 hours later, 5 mCi of 35S-methionine and 5 mCi 35S-cysteine (available from Amersham) are added. The cells are further

5

-56-

10

incubated for 16 hours and then they are harvested by centrifugation. The polypeptides in the supernatant as well as the intracellular polypeptides are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

15

5 Microsequencing of the amino acid sequence of the amino terminus of purified polypeptide can be used to determine the amino terminal sequence of the mature polypeptide and thus the cleavage point and length of the secretory signal peptide.

20

10

**Example 3: Cloning and Expression of Wnt-4AF and Wnt-5C Homolog in Mammalian Cells**

25

A typical mammalian expression vector contains at least one promoter element, which mediates the initiation of transcription of mRNA, the polypeptide coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing.

30

35

20 Highly efficient transcription can be achieved with the early and late promoters from SV40, the long terminal repeats (LTRS) from Retroviruses, e.g., RSV, HTLVII, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter). Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pIRES1neo, pRetro-Off, pRetro-On, PLXSN, or pLNCK (Clonetech Labs, Palo Alto, CA), pcDNA3.1 (+/-), pcDNA/Zeo (+/-) or pcDNA3.1/Hygro (+/-) (Invitrogen), PSVL

40

45

50

55

-57-

and PMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152),  
pSV2dhfr (ATCC 37146) and pBC12MI (ATCC 67109). Mammalian  
host cells that could be used include human Hela 293, H9 and  
Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and  
CV 1, quail QC1-3 cells, mouse L cells and Chinese hamster  
ovary (CHO) cells.

Alternatively, the gene can be expressed in stable cell  
lines that contain the gene integrated into a chromosome.  
The co-transfection with a selectable marker such as dhfr,  
gpt, neomycin, or hygromycin allows the identification and  
isolation of the transfected cells.

The transfected gene can also be amplified to express  
large amounts of the encoded polypeptide. The DHFR  
(dihydrofolate reductase) marker is useful to develop cell  
lines that carry several hundred or even several thousand  
copies of the gene of interest. Another useful selection  
marker is the enzyme glutamine synthase (GS) (Murphy, et  
al., Biochem. J. 227:277-279 (1991); Bebbington, et al.,  
Bio/Technology 10:169-175 (1992)). Using these markers, the  
mammalian cells are grown in selective medium and the cells  
with the highest resistance are selected. These cell lines  
contain the amplified gene(s) integrated into a chromosome.  
Chinese hamster ovary (CHO) and NSO cells are often used  
for the production of polypeptides.

The expression vectors pC1 and pC4 contain the strong  
promoter (LTR) of the Rous Sarcoma Virus (Cullen, et al.,  
Molec. Cell. Biol. 5:438-447 (1985)) plus a fragment of the  
CMV-enhancer (Boshart, et al., Cell 41:521-530 (1985)).  
Multiple cloning sites, e.g., with the restriction enzyme

-58-

cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors contain in addition the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene.

**Example 3(a): Cloning and Expression in COS Cells**

The expression plasmid, pWnt-4AF and Wnt-5C homolog HA, is made by cloning a cDNA encoding Wnt-4AF and Wnt-5C homolog into the expression vector pcDNAI/Amp or pcDNAIII (which can be obtained from Invitrogen, Inc.).

The expression vector pcDNAI/amp contains: (1) an E. coli origin of replication effective for propagation in E. coli and other prokaryotic cells; (2) an ampicillin resistance gene for selection of plasmid-containing prokaryotic cells; (3) an SV40 origin of replication for propagation in eucaryotic cells; (4) a CMV promoter, a polylinker, an SV40 intron; (5) several codons encoding a hemagglutinin fragment (i.e., an "HA" tag to facilitate purification) or HIS tag (see, e.g, Ausubel, supra) followed by a termination codon and polyadenylation signal arranged so that a cDNA can be conveniently placed under expression control of the CMV promoter and operably linked to the SV40 intron and the polyadenylation signal by means of restriction sites in the polylinker. The HA tag corresponds to an epitope derived from the influenza hemagglutinin polypeptide described by Wilson, et al., Cell 37:767-778 (1984). The fusion of the HA tag to the target polypeptide allows easy detection and recovery of the recombinant polypeptide with an antibody that recognizes the HA epitope.

-59-

pcDNAIII contains, in addition, the selectable neomycin marker.

A DNA fragment encoding the Wnt-4AF and Wnt-5C homolog is cloned into the polylinker region of the vector so that recombinant polypeptide expression is directed by the CMV promoter. The plasmid construction strategy is as follows.

The Wnt-4AF and Wnt-5C homolog cDNA of the deposited clone is amplified using primers that contain convenient restriction sites, much as described above for construction of vectors for expression of Wnt-4AF and Wnt-5C homolog in *E. coli*. Non-limiting examples of suitable primers include those based on the coding sequences presented in at least one of SEQ ID NOS:1, 3, 5, & 7 as they encode Wnt-4AF and Wnt-5C homolog polypeptides as described herein.

The PCR amplified DNA fragment and the vector, pcDNAI/Amp, are digested with suitable restriction enzyme(s) and then ligated. The ligation mixture is transformed into *E. coli* strain SURE (available from Stratagene Cloning Systems, 11099 North Torrey Pines Road, La Jolla, CA 92037), and the transformed culture is plated on ampicillin media plates which then are incubated to allow growth of ampicillin resistant colonies. Plasmid DNA is isolated from resistant colonies and examined by restriction analysis or other means for the presence of the Wnt-4AF and Wnt-5C homolog-encoding fragment.

For expression of recombinant Wnt-4AF and Wnt-5C homolog, COS cells are transfected with an expression vector, as described above, using DEAE-DEXTRAN, as described, for instance, in Sambrook, et al., Molecular

5

-60-

10

Cloning: a Laboratory Manual, Cold Spring Laboratory Press, Cold Spring Harbor, New York (1989). Cells are incubated under conditions for expression of Wnt-4AF and Wnt-5C homolog by the vector.

15

20

25

30

35

5 Expression of the Wnt-4AF and Wnt-5C homolog-HA fusion polypeptide is detected by radiolabeling and immunoprecipitation, using methods described in, for example Harlow, et al., Antibodies: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1988). To this end, two days after transfection, the cells are labeled by incubation in media containing 35S-cysteine for 8 hours. The cells and the media are collected, and the cells are washed and lysed with detergent-containing RIPA buffer: 150 mM NaCl, 1% NP-40, 15 0.1% SDS, 0.5% DOC, 50 mM TRIS, pH 7.5, as described by Wilson, et al. cited above. Proteins are precipitated from the cell lysate and from the culture media using an HA-specific monoclonal antibody. The precipitated polypeptides then are analyzed by SDS-PAGE and autoradiography. An 20 expression product of the expected size is seen in the cell lysate, which is not seen in negative controls.

40

#### **Example 3(b): Cloning and Expression in CHO Cells**

45

50

The vector pC4 is used for the expression of Wnt-4AF 25 and Wnt-5C homolog polypeptide. Plasmid pC4 is a derivative of the plasmid pSV2-dhfr (ATCC Accession No. 37146). The plasmid contains the mouse DHFR gene under control of the SV40 early promoter. Chinese hamster ovary- or other cells lacking dihydrofolate activity that are transfected with

55



5

-61-

10

15

20

25

30

35

40

45

50

these plasmids can be selected by growing the cells in a selective medium (alpha minus MEM, Life Technologies) supplemented with the chemotherapeutic agent methotrexate. The amplification of the DHFR genes in cells resistant to methotrexate (MTX) has been well documented (see, e.g., F. W. Alt, et al., J. Biol. Chem. 253:1357-1370 (1978); J. L. Hamlin and C. Ma, Biochem. et Biophys. Acta 1097:107-143 (1990); and M. J. Page and M. A. Sydenham, Biotechnology 9:64-68 (1991)). Cells grown in increasing concentrations of MTX develop resistance to the drug by overproducing the target enzyme, DHFR, as a result of amplification of the DHFR gene. If a second gene is linked to the DHFR gene, it is usually co-amplified and over-expressed. It is known in the art that this approach can be used to develop cell lines carrying more than 1,000 copies of the amplified gene(s). Subsequently, when the methotrexate is withdrawn, cell lines are obtained which contain the amplified gene integrated into one or more chromosome(s) of the host cell.

Plasmid pC4 contains for expressing the gene of interest the strong promoter of the long terminal repeat (LTR) of the Rous Sarcoma Virus (Cullen, et al., Molec. Cell. Biol. 5:438-447 (1985)) plus a fragment isolated from the enhancer of the immediate early gene of human cytomegalovirus (CMV) (Boshart, et al., Cell 41:521-530 (1985)). Downstream of the promoter are BamHI, XbaI, and Asp718 restriction enzyme cleavage sites that allow integration of the genes. Behind these cloning sites the plasmid contains the 3' intron and polyadenylation site of the rat preproinsulin gene. Other high efficiency promoters

55

5

-62-

10

can also be used for the expression, e.g., the human b-actin promoter, the SV40 early or late promoters or the long terminal repeats from other retroviruses, e.g., HIV and HTLVI. Clontech's Tet-Off and Tet-On gene expression

15

5 systems and similar systems can be used to express the Wnt-4AF and Wnt-5C homolog in a regulated way in mammalian cells (M. Gossen, and H. Bujard, Proc. Natl. Acad. Sci. USA 89: 5547-5551 (1992)). For the polyadenylation of the mRNA

20

other signals, e.g., from the human growth hormone or globin

10

genes can be used as well. Stable cell lines carrying a gene of interest integrated into the chromosomes can also be

25

selected upon co-transfection with a selectable marker such as gpt, G418 or hygromycin. It is advantageous to use more than one selectable marker in the beginning, e.g., G418 plus

15 methotrexate.

30

The plasmid pC4 is digested with restriction enzymes and then dephosphorylated using calf intestinal phosphatase by procedures known in the art. The vector is then isolated from a 1% agarose gel.

35

20 The DNA sequence encoding the complete Wnt-4AF and Wnt-5C homolog polypeptide is amplified using PCR

40

oligonucleotide primers corresponding to the 5' and 3' sequences of the gene. Non-limiting examples include 5' and 3' primers having nucleotides corresponding or complementary

25 to a portion of the coding sequence of a Wnt-4AF and Wnt-5C homolog, e.g., as presented in at least one of SEQ ID NOS:1, 3, 5, & 7 according to known method steps.

45

The amplified fragment is digested with suitable endonucleases and then purified again on a 1% agarose gel.

50

55

-63-

The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC4 using, for instance, restriction enzyme analysis.

Chinese hamster ovary (CHO) cells lacking an active DHFR gene are used for transfection. 5 µg of the expression plasmid pC4 is cotransfected with 0.5 µg of the plasmid pSV2-neo using lipofectin. The plasmid pSV2neo contains a dominant selectable marker, the neo gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 µg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 µg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 mM, 2 mM, 5 mM, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 mM. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reverse phase HPLC analysis.

5

-64-

**Example 4: Tissue Distribution of Wnt-4AF and Wnt-5C  
Homolog mRNA Expression**

10

15

20

25

30

35

40

45

50

55

Northern blot analysis is carried out to examine Wnt-4AF and Wnt-5C homolog gene expression in human tissues, using methods described by, among others, Sambrook, et al., cited above. A cDNA probe containing the entire nucleotide sequence of a Wnt-4AF and Wnt-5C homolog polypeptide (SEQ ID NOS:1, 3, 5, & 7) is labeled with <sup>32</sup>P using the Rediprime™ DNA labeling system (Amersham Life Science), according to the manufacturer's instructions. After labeling, the probe is purified using a CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to the manufacturer's protocol number PT1200-1. The purified and labeled probe is used to examine various human tissues for Wnt-4AF and Wnt-5C homolog mRNA.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) are obtained from Clontech and are examined with the labeled probe using ExpressHyb hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and films developed according to standard procedures. The results show Wnt-4AF and Wnt-5C homolog polypeptides to be selectively expressed in at least one of small intestine, nose, stomach, gallbladder, lung and other tissues.

It will be clear that the invention can be practiced otherwise than as particularly described in the foregoing description and examples.

5

-65-

10

Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

15

20

25

30

35

40

45

50

55

**Claims**

5

10

15

20

25

30

35

40

45

50

55

5

-66-

What is claimed is:

10

1. An isolated nucleic acid, comprising at least one Wnt-4AF and Wnt-5C homolog polynucleotide encoding at least 90-100% of the contiguous amino acids of a protein sequence of SEQ ID NOS:2, 4, 6 & 8.

15

20

2. An isolated nucleic acid, comprising at least one Wnt-4AF and Wnt-5C homolog polynucleotide encoding at least 90-100% of the contiguous amino acids of a protein sequence selected from at least one of SEQ ID NOS:2, 4, 6 & 8, further comprising at least one mutation corresponding to at least one substitution, insertion or deletion of SEQ ID NOS:2, 4, 6 & 8.

25

30

3. An isolated nucleic acid, comprising at least one Wnt-4AF and Wnt-5C homolog polynucleotide comprising or complementary to at least 90-100% of the contiguous nucleotides of at least one of SEQ ID NOS:1, 3, 5, & 7.

35

4. A composition, comprising at least one isolated nucleic acid according to any of claims 1-3 and a carrier or diluent.

20

5. A recombinant vector, comprising at least one nucleic acid according to any of claims 1-3.

40

6. A host cell comprising at least one recombinant vector according to claim 5.

45

7. A method for producing at least one Wnt-4AF and Wnt-5C homolog polypeptide, comprising culturing a host cell according to claim 6 under conditions that the at least one Wnt-4AF and Wnt-5C homolog polypeptide is expressed in detectable or recoverable amounts.

50

55

-67-

8. A transgenic or chimeric non-human animal,  
comprising at least one isolated nucleic acid according to  
any of claims 1-3.

9. An isolated polypeptide, comprising a Wnt-4AF  
and Wnt-5C homolog polypeptide comprising at least 90-100%  
of the contiguous amino acids of SEQ ID NOS:2, 4, 6 & 8.

10. An isolated polypeptide according to claim 9,  
further comprising at least one mutation corresponding to at  
least one substitution, insertion or deletion of SEQ ID  
NOS:2, 4, 6 & 8.

11. An isolated polypeptide comprising at least  
one polypeptide comprising at least 90-100% of the  
contiguous amino acids of at least one extracellular,  
intracellular, transmembrane or active domain of SEQ ID  
NOS:2, 4, 6 & 8.

12. A composition, comprising at least one  
isolated polypeptide according to any of claims 8-11 and a  
carrier or diluent.

13. An isolated nucleic acid probe, fragment, or  
primer, comprising a Wnt-4AF and Wnt-5C homolog  
polynucleotide comprising a sequence corresponding or  
complementary to at least 10 nucleotides of SEQ ID NOS:1, 3,  
5, & 7.

14. An isolated nucleic acid, comprising a nucleic  
acid that hybridizes under stringent conditions to a nucleic  
acid according to claim 13.

15. An antibody or at least one fragment thereof  
that binds an epitope specific to at least one Wnt-4AF and  
Wnt-5C homolog polypeptide according to any of claims 8-11.



5

-68-

10

16. A host cell, expressing at least one antibody  
or at least one fragment thereof according to claim 15.

17. A method for producing at least one antibody,  
comprising culturing a host cell according to claim 16.

15

5

18. A method for identifying compounds that bind  
at least one Wnt-4AF and Wnt-5C homolog polypeptide,  
comprising

20

(a) admixing at least one isolated Wnt-4AF and  
Wnt-5C homolog polypeptide according to any of claims 8-11  
with at least one test compound or composition; and

25

(b) detecting at least one binding interaction  
between said at least one Wnt-4AF and Wnt-5C homolog  
polypeptide and the test compound or composition.

30

19. A compound or composition detected by method  
according to claim 18.

20. Any invention described herein.

35

40

45

50

55

## SEQUENCE LISTING

<110> Eli Lilly and Company

<120> Mnt HOMOLOG NUCLEIC ACIDS, POLYPEPTIDES, METHODS, USES

<130> X12138 PCT Sequence Listing

<140>

<141>

<150> 60/098453

<151> 1998-08-31

<150> 60/098440

<151> 1998-08-31

<150> 60/106462

<151> 1998-10-30

<150> 60/111588

<151> 1998-12-09

<160> 8

<170> MS-DOS Text

<210> 1

<211> 1228

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (2)..(1054)

<400> 1

catgagtcctc cgctcgtgcc tgcgttcgct gcgcctcctc gtcttcgccc tcttctcagc 60

cgccgcgagc aactggctgt acctggccaa gctgtcgtcg gtggggagca tctcagagga 120

ggagacgtgc gagaaactca agggcctgat ccagaggcag gtgcagatgt gcaagcggaa 180

cctggaaagt atggactcgg tgcgcgcggg tgcccagctg gccattgagg agtgccagta 240

ccagttcccg aaccggcgct ggaactgctc cacactcgac tccttgcccc tcttcggcaa 300

ggtggtgacg caagggactc gggaggcggc cttcgtgtac gccatctctt cggcaggtgt 360

ggccttttga gtgacgcggg cgtgcagcag tggggagctg gagaagtgcg gctgtgacag 420

gacagtgcac ggggtcagcc cacagggtct ccagtgggtc ggtgtgctctg acaacatcgc 480

ctacggtgtg gccttctcac agtcgtttgt ggtgtgctcg gagagaagca agggggcctc 540

gtccagcaga gccctcatga acctccacaa caatgaggcc ggcagggaag ccattctgac 600

acacatgcgg gtggaatgca agtgccacgg ggtgtcagcc tcctgtgagg taagacgtg 660

ctggcgagcc gtgcgcctct tccgccaggt ggtgcacgca ctgaaggaga agtttgatgg 720

tgccactgag ttggagccac gccgcgtggg ctctccagg gcaactggtg cagcgaacgc 780

acagttcaag ccgcacacag atgaggacct ggtgtacttg gagcctagcc ccgacttctg 840

tgagcaggac atgcgcagcg gcgtgctggg cagcaggggc cgcacatgca acaagacgtc 900

caagggccatc gacggctgtg agctgctgtg ctgtggccgc ggcttcaca cggcgaggt 960

ggagctggct gaacgctgca gctgcaaatt ccactggtgc tgcttcgtca agtgccggca 1020

gtgccagcgg ctctggaggt tgcacacgtg ccgatgaccg cctgcctagc cctgcgcgg 1080

caaccaccta gtggcccgag gaaggccgat aatttaaaca gtctccacc acctaccca 1140

agagatactg gttgtatttt ttgttctggt ttggtttttg ggtcctcatg ttatttattg 1200

ccgaaaccag gcaggcaacc ccaagggc 1228

<210> 2

<211> 351

<212> PRT

<213> Homo sapiens

<400> 2  
Met Ser Pro Arg Ser Cys Leu Arg Ser Leu Arg Leu Leu Val Phe Ala  
1 5 10 15  
Val Phe Ser Ala Ala Ala Ser Asn Trp Leu Tyr Leu Ala Lys Leu Ser  
20 25 30  
Ser Val Gly Ser Ile Ser Glu Glu Glu Thr Cys Glu Lys Leu Lys Gly  
35 40 45  
Leu Ile Gln Arg Gln Val Gln Met Cys Lys Arg Asn Leu Glu Val Met  
50 55 60  
Asp Ser Val Arg Arg Gly Ala Gln Leu Ala Ile Glu Glu Cys Gln Tyr  
65 70 75 80  
Gln Phe Arg Asn Arg Arg Trp Asn Cys Ser Thr Leu Asp Ser Leu Pro  
85 90 95  
Val Phe Gly Lys Val Val Thr Gln Gly Thr Arg Glu Ala Ala Phe Val  
100 105 110  
Tyr Ala Ile Ser Ser Ala Gly Val Ala Phe Ala Val Thr Arg Ala Cys  
115 120 125  
Ser Ser Gly Glu Leu Glu Lys Cys Gly Cys Asp Arg Thr Val His Gly  
130 135 140  
Val Ser Pro Gln Gly Phe Gln Trp Ser Gly Cys Ser Asp Asn Ile Ala  
145 150 155 160  
Tyr Gly Val Ala Phe Ser Gln Ser Phe Val Asp Val Arg Glu Arg Ser  
165 170 175  
Lys Gly Ala Ser Ser Ser Arg Ala Leu Met Asn Leu His Asn Asn Glu  
180 185 190  
Ala Gly Arg Lys Ala Ile Leu Thr His Met Arg Val Glu Cys Lys Cys  
195 200 205  
His Gly Val Ser Gly Ser Cys Glu Val Lys Thr Cys Trp Arg Ala Val  
210 215 220  
Pro Pro Phe Arg Gln Val Gly His Ala Leu Lys Glu Lys Phe Asp Gly  
225 230 235 240  
Ala Thr Glu Val Glu Pro Arg Arg Val Gly Ser Ser Arg Ala Leu Val  
245 250 255  
Pro Arg Asn Ala Gln Phe Lys Pro His Thr Asp Glu Asp Leu Val Tyr  
260 265 270  
Leu Glu Pro Ser Pro Asp Phe Cys Glu Gln Asp Met Arg Ser Gly Val  
275 280 285  
Leu Gly Thr Arg Gly Arg Thr Cys Asn Lys Thr Ser Lys Ala Ile Asp  
290 295 300  
Gly Cys Glu Leu Leu Cys Cys Gly Arg Gly Phe His Thr Ala Gln Val  
305 310 315 320  
Glu Leu Ala Glu Arg Cys Ser Cys Lys Phe His Trp Cys Cys Phe Val

325 330 335  
 Lys Cys Arg Gln Cys Gln Arg Leu Val Glu Leu His Thr Cys Arg  
 340 345 350

<210> 3  
 <211> 1340  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> CDS  
 <222> (63)..(1139)

<400> 3  
 gtcaggggaac cctactcttg aaactgtcag tcccagggca ctggggaggg ctgaggccga 60  
 ccatgccccag cctgctgctg ctgttcacgg ctgctctgct gtccagctgg gctcagcttc 120  
 tgacagacgc caactcctgg tggtcattag ctttgaaccc ggtgcagaga cccgagatgt 180  
 ttatcatcgg tgcccagccc gtgtgcagtc agcttccccg gctctcccc ttgcccagagga 240  
 agctgtggca attgtaccag gagcacatgg cctacatagg ggaggaggcc aagactggca 300  
 tcaaggaaag ccagcaccag ttccggcagc ggcgggtggaa ttgcagcaca gcggacaacg 360  
 catctgtctt tgggagagtc atgcagatag gcagccgaga gaccgccttc acccagcggg 420  
 tgagcgccgc gggcgtgggc aacgccatca gccgggcctg ccgcgagggc gagctctcca 480  
 cctgcggtg cagccggacg gcgcggccca aggacctgcc ccgggactgg ctgtggggcg 540  
 gctgtgggga caacgtggag tacggctacc gcttcgocaa ggagtttgtg gatgcccggg 600  
 agcgagagaa gaactttgcc aaagatcag aggagcaggg ccgggtgctc atgaacctgc 660  
 aaaacaacga gggcgggtgc agggctgtgt ataagatggc agacgtagcc tgcaaatgcc 720  
 acggcgcttc ggggtcctgc agcctcaaga cctgctggct gcagctggcc gagttccgca 780  
 aggtcgggga ccggctgaag gagaagtacg acagcgccgc cgccatgcgc gtcacccgca 840  
 agggccgggt ggagctggct aacagccgct taccacagcc caccgccggg gacctggtct 900  
 atgtggaccc cagccccgac tactgcctgc gcaacgagag caccggctcc ctgggcacgc 960  
 agggccgctc ctgcaacaag acctcggagg gcatggatgg ctgtgagctc atgtgctgcg 1020  
 ggcgtggcta caaccagttc aagagcgtgc aggtggagcg ctgccactgc aagttccact 1080  
 ggtgctgctt cgtcaggtgt aagaagtgca cggagatcgt ggaccagtac atctgtatat 1140  
 agccccgagg gcctgctccc gggccctgc actctgcctc acaaggtctc atattatata 1200  
 aatctatata aatctatttt atatttgtat aagtaaatgg gtgggtgcta tacaatggaa 1260  
 agatgaaaat ggaagggaag agcttattta agagacgctg gagatctctg aggagtgga 1320  
 ttgtcgggtt ctctcctctt 1340

<210> 4  
 <211> 359  
 <212> PRT  
 <213> Homo sapiens

<400> 4  
 Met Pro Ser Leu Leu Leu Phe Thr Ala Ala Leu Leu Ser Ser Trp  
 1 5 10 15  
 Ala Gln Leu Leu Thr Asp Ala Asn Ser Trp Trp Ser Leu Ala Leu Asn  
 20 25 30  
 Pro Val Gln Arg Pro Glu Met Phe Ile Ile Gly Ala Gln Pro Val Cys  
 35 40 45  
 Ser Gln Leu Pro Gly Leu Ser Pro Gly Gln Arg Lys Leu Cys Gln Leu  
 50 55 60  
 Tyr Gln Glu His Met Ala Tyr Ile Gly Glu Gly Ala Lys Thr Gly Ile  
 65 70 75 80  
 Lys Glu Cys Gln His Gln Phe Arg Gln Arg Arg Trp Asn Cys Ser Thr  
 85 90 95

Ala Asp Asn Ala Ser Val Phe Gly Arg Val Met Gln Ile Gly Ser Arg  
 100 105 110

Glu Thr Ala Phe Thr His Ala Val Ser Ala Ala Gly Val Val Asn Ala  
 115 120 125

Ile Ser Arg Ala Cys Arg Glu Gly Glu Leu Ser Thr Cys Gly Cys Ser  
 130 135 140

Arg Thr Ala Arg Pro Lys Asp Leu Pro Arg Asp Trp Leu Trp Gly Gly  
 145 150 155 160

Cys Gly Asp Asn Val Glu Tyr Gly Tyr Arg Phe Ala Lys Glu Phe Val  
 165 170 175

Asp Ala Arg Glu Arg Glu Lys Asn Phe Ala Lys Gly Ser Glu Glu Gln  
 180 185 190

Gly Arg Val Leu Met Asn Leu Gln Asn Asn Glu Ala Gly Arg Arg Ala  
 195 200 205

Val Tyr Lys Met Ala Asp Val Ala Cys Lys Cys His Gly Val Ser Gly  
 210 215 220

Ser Cys Ser Leu Lys Thr Cys Trp Leu Gln Leu Ala Glu Phe Arg Lys  
 225 230 235 240

Val Gly Asp Arg Leu Lys Glu Lys Tyr Asp Ser Ala Ala Ala Met Arg  
 245 250 255

Val Thr Arg Lys Gly Arg Leu Glu Leu Val Asn Ser Arg Phe Thr Gln  
 260 265 270

Pro Thr Pro Glu Asp Leu Val Tyr Val Asp Pro Ser Pro Asp Tyr Cys  
 275 280 285

Leu Arg Asn Glu Ser Thr Gly Ser Leu Gly Thr Gln Gly Arg Leu Cys  
 290 295 300

Asn Lys Thr Ser Glu Gly Met Asp Gly Cys Glu Leu Met Cys Cys Gly  
 305 310 315 320

Arg Gly Tyr Asn Gln Phe Lys Ser Val Gln Val Glu Arg Cys His Cys  
 325 330 335

Lys Phe His Trp Cys Cys Phe Val Arg Cys Lys Lys Cys Thr Glu Ile  
 340 345 350

Val Asp Gln Tyr Ile Cys Lys  
 355

<210> 5  
 <211> 1205  
 <212> DNA  
 <213> Homo sapiens

<400> 5  
 taagctcgga attcggctcg aggcgaattc cactgggtgt gcttcgtcaa gtgccggcag 60  
 tgccagcggc tegtggagtt gcacacgtgc ccatgaccgc ctgcctagcc ctgcgcccgc 120  
 aaccacctag tggcccaggg aaggccgata atttaaacag tctcccacca cctaccccaa 180  
 gagatactgg ttgtattttt tgttctggtt tggtttttgg gtcctcatgt tatttattgc 240

```

cgaaaccagg caggcaaccc caagggcacc aaccagggcc tccccaaagc ctgggccttt 300
gtggctgcca ctgaccaaag ggaccttgct cgtgccgctg gctgcccga tgtggctgcc 360
actgaccact cagtgttat ctgtgtccgt ttttctactt gcagacctaa ggtggagtaa 420
caaggagtat taccaccaca tggctactga ccgtgtcatc ggggaagagg gggccttatg 480
gcagggaaaa taggtaccga cttgatggaa gtcacaccct ctggaaaaaa agaactctta 540
actctccagc acacatacac atggactcct ggcagcttga gcctagaagc catgtctctc 600
aaatgccctg agaaagggaa caagcagata ccagggtcaag ggcaccagat tcatttcagc 660
ccttacatgg acagctagag gttcgatata tgtgggtcct tccaggcaag aagagggaga 720
tgagagcaag agacgactga agtccccacc tagaaccacg cctgccccag cctgccccctg 780
ggaagaggaa acttaaccac tccccagacc cacctaggca ggcatatagg ctgccatcct 840
ggaccaggga tcccggtgtg gcctttgcag tcatgcccga gtcacctttc acagcgctgt 900
tcctccatga aactgaaaaa cacacacaca cacacacaca cacacacaca cacacacaca 960
cacggacaca cacacacacc tgcgagagag agggaggaaa gggctgtgcc ttgcagtca 1020
tgccccagtc acctttcaca gcaactgttc tccatgaaac tgaanaagga aaacacacac 1080
acacacacct gcgagaggga gggaggaaaag ggctgtgcaa taaagtcttc tccccattaa 1140
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1200
aaaaaa                                     1205

```

```

<210> 6
<211> 351
<212> PRT
<213> Homo sapiens

```

```

<400> 6
Met Ser Pro Arg Ser Cys Leu Arg Ser Leu Arg Leu Leu Val Phe Ala
 1             5             10             15

Val Phe Ser Ala Ala Ala Ser Asn Trp Leu Tyr Leu Ala Lys Leu Ser
      20             25             30

Ser Val Gly Ser Ile Ser Glu Glu Glu Thr Cys Glu Lys Leu Lys Gly
      35             40             45

Leu Ile Gln Arg Gln Val Gln Met Cys Lys Arg Asn Leu Glu Val Met
      50             55             60

Asp Ser Val Arg Arg Gly Ala Gln Leu Ala Ile Glu Glu Cys Gln Tyr
      65             70             75             80

Gln Phe Arg Asn Arg Arg Trp Asn Cys Ser Thr Leu Asp Ser Leu Pro
      85             90             95

Val Phe Gly Lys Val Val Thr Gln Gly Thr Arg Glu Ala Ala Phe Val
      100            105            110

Tyr Ala Ile Ser Ser Ala Gly Val Ala Phe Ala Val Thr Arg Ala Cys
      115            120            125

Ser Ser Gly Glu Leu Glu Lys Cys Gly Cys Asp Arg Thr Val His Gly
      130            135            140

Val Ser Pro Gln Gly Phe Gln Trp Ser Gly Cys Ser Asp Asn Ile Ala
      145            150            155            160

Tyr Gly Val Ala Phe Ser Gln Ser Phe Val Asp Val Arg Glu Arg Ser
      165            170            175

Lys Gly Ala Ser Ser Ser Arg Ala Leu Met Asn Leu His Asn Asn Glu
      180            185            190

Ala Gly Arg Lys Ala Ile Leu Thr His Met Arg Val Glu Cys Lys Cys
      195            200            205

```

His Gly Val Ser Gly Ser Cys Glu Val Lys Thr Cys Trp Arg Ala Val  
 210 215 220

Pro Pro Phe Arg Gln Val Gly His Ala Leu Lys Glu Lys Phe Asp Gly  
 225 230 235 240

Ala Thr Glu Val Glu Pro Arg Arg Val Gly Ser Ser Arg Ala Leu Val  
 245 250 255

Pro Arg Asn Ala Gln Phe Lys Pro His Thr Asp Glu Asp Leu Val Tyr  
 260 265 270

Leu Glu Pro Ser Pro Asp Phe Cys Glu Gln Asp Ile Arg Ser Gly Val  
 275 280 285

Leu Gly Thr Arg Gly Arg Thr Cys Asn Lys Thr Ser Lys Ala Ile Asp  
 290 295 300

Gly Cys Glu Leu Leu Cys Cys Gly Arg Gly Phe His Thr Ala Gln Val  
 305 310 315 320

Glu Ala Arg Asn Ser Ala Arg Gly Lys Phe His Trp Cys Cys Phe Val  
 325 330 335

Lys Cys Arg Gln Cys Gln Arg Leu Val Glu Leu His Thr Cys Arg  
 340 345 350

<210> 7  
 <211> 1239  
 <212> DNA  
 <213> Homo sapiens

<400> 7  
 cgggagcctt gcggcgcgtg ccccgggctg ggcgcgcacg gcaccatgag ccccggttcg 60  
 tgccctgcgt cctcgcgact cctcgctctc gccgtgttct cggccgcgcg gagcaattgg 120  
 ctgtacctgg ccaagctgtc atcgggtggc agcatctccg aagaggagac gtgcgagaaa 180  
 ctcaaaggcc tgatccagag gcaggtgcag atgtgcaaac ggaaccttga ggtgatggac 240  
 tcagtcgccc gtggtgcccc gctggccatc gaggagtgcc aataccagtt ccggaaccgg 300  
 cgctggaact gtccacact ggactccctc cctgtctttg ggaaggtggt gacacaaggg 360  
 acccgggagg cggcctttgt atacgccatc tcttcagcag gtggcctttg cagtgcacgg 420  
 ggcgtgcagc agtggggagc tggagaagtg cggctgtgac aggacagtgc atgggggtcag 480  
 cccacagggc ttccagtggc caggatgctc tgacaacatc gcctacgggt tggccttctc 540  
 acagtcgttt gtggatgtgc gggagagaag caagggggcc tcgtccagca gagccctcat 600  
 gaacctccac aacaatgagg ccggcaggaa ggccatcctg acacacatgc ggggtggaatg 660  
 caagtgcac cgggtgtcag gctcctgtga ggtaaagacg tgctggcgag ccgtgccgcc 720  
 ctcccgccag gtgggtcacg cactgaagga gaagtttgat ggtgccactg aggtggagcc 780  
 acgccgcgtg ggctcctcca gggcactggt gccacgcaac gcacagtcca agccgcacac 840  
 agatgaggac ctggtgtact tggagcctag ccccgacttc tgtgagcagg acatgcgcag 900  
 cggcgtgctg ggcacgagg gcccacatg caacaagacg tccaaggcca tcgacggctg 960  
 tgagctgctg tgctgtggcc gcggcttcca cagggcgacg gtggagctgg ctgaacgctg 1020  
 cagctgcaaa ttccactggt gctgcttcgt caagtcccg cagtgccagc ggctcgtgga 1080  
 gttgcacacg tgcgatgac gcctgccta gccctgcgcc ggcaaccacc tagtgggcca 1140  
 ggggaaggcg ataatttaa cagtctccca ccacctaaaa aaaaaaaaaa aaaaaaaaaa 1200  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1239

<210> 8  
 <211> 351  
 <212> PRT  
 <213> Homo sapiens

<400> 8  
 Met Ser Pro Arg Ser Cys Leu Arg Ser Leu Arg Leu Leu Val Phe Ala

1	5	10	15
Val Phe Ser	Ala Ala Ala	Ser Asn Trp	Leu Tyr Leu Ala Lys Leu Ser
	20	25	30
Ser Val Gly	Ser Ile Ser	Glu Glu Glu	Thr Cys Glu Lys Leu Lys Gly
	35	40	45
Leu Ile Gln	Arg Gln Val	Gln Met Cys	Lys Arg Asn Leu Glu Val Met
	50	55	60
Asp Ser Val	Arg Arg Gly	Ala Gln Leu	Ala Ile Glu Glu Cys Gln Tyr
	65	70	75
Gln Phe Arg	Asn Arg Arg	Trp Asn Cys	Ser Thr Leu Asp Ser Leu Pro
	85	90	95
Val Phe Gly	Lys Val Val	Thr Gln Gly	Thr Arg Glu Ala Ala Phe Val
	100	105	110
Tyr Ala Ile	Ser Ser Ala	Gly Val Ala	Phe Ala Val Thr Arg Ala Cys
	115	120	125
Ser Ser Gly	Glu Leu Glu	Lys Cys Gly	Cys Asp Arg Thr Val His Gly
	130	135	140
Val Ser Pro	Gln Gly Phe	Gln Trp Ser	Gly Cys Ser Asp Asn Ile Ala
	145	150	155
Tyr Gly Val	Ala Phe Ser	Gln Ser Phe	Val Asp Val Arg Glu Arg Ser
	165	170	175
Lys Gly Ala	Ser Ser Ser	Arg Ala Leu	Met Asn Leu His Asn Asn Glu
	180	185	190
Ala Gly Arg	Lys Ala Ile	Leu Thr His	Met Arg Val Glu Cys Lys Cys
	195	200	205
His Gly Val	Ser Gly Ser	Cys Glu Val	Lys Thr Cys Trp Arg Ala Val
	210	215	220
Pro Pro Phe	Arg Gln Val	Gly His Ala	Leu Lys Glu Lys Phe Asp Gly
	225	230	235
Ala Thr Glu	Val Glu Pro	Arg Arg Val	Gly Ser Ser Arg Ala Leu Val
	245	250	255
Pro Arg Asn	Ala Gln Phe	Lys Pro His	Thr Asp Glu Asp Leu Val Tyr
	260	265	270
Leu Glu Pro	Ser Pro Asp	Phe Cys Glu	Gln Asp Met Arg Ser Gly Val
	275	280	285
Leu Gly Thr	Arg Gly Arg	Thr Cys Asn	Lys Thr Ser Lys Ala Ile Asp
	290	295	300
Gly Cys Glu	Leu Leu Cys	Cys Gly Arg	Gly Phe His Thr Ala Gln Val
	305	310	315
Glu Leu Ala	Glu Arg Cys	Ser Cys Lys	Phe His Trp Cys Cys Phe Val
	325	330	335
Lys Cys Arg	Gln Cys Gln	Arg Leu Val	Glu Leu His Thr Cys Arg



WO 00/12117

PCT/US99/19046

340

345

350

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19046

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5, 23.24.3, 24.31; 435/7.1, 320.1, 325, 252.3, 69.1, 69.3; 800/13; 530/350, 395, 387.1, 387.9; 514/2, 12

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
WEST US Patent database; GenEMBL sequence databases

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	YOSHIOKA, H. et al. Regional expression of the Cwnt-4 gene in developing chick central nervous system in relationship to the diencephalic neuromere D2 and a dorsal domain of the spinal cord. Biochemical and Biophysical Research Communications. 30 September 1994, Vol. 203, No. 3, pages 1581-1588, see entire document.	1-7, 9-11, 13, 14, 20
X	CHRISTIAN, J. L. et al. Isolation of cDNAs partially encoding four Xenopus Wnt-1/int-1-related proteins and characterization of their transient expression during embryonic development. Developmental Biology. 1991, Vol. 143, pages 230-234, see entire document.	1-7, 9-11, 13, 14, 20

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\*

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\*

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\*

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*A\*

document member of the same patent family

Date of the actual completion of the international search

03 DECEMBER 1999

Date of mailing of the international search report

02 FEB 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ELIZABETH C. KEMMERER

Telephone No. (703) 308-0196

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19046

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 12, 15-19  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

International application No.  
PCT/US99/19046

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (6):

A61K 38/17, 38.18; C07K 14/435, 14/475; C12N 1/21, 5/10, 15/12, 15/64, 15/66; G01N 33/53

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL :

536/23.1, 23.5, 23.24.3, 24.31; 435/7.1, 320.1, 325, 252.3, 69.1, 69.3; 800/13; 530/350, 395, 387.1, 387.9; 514/2, 12